Abstract
Neurons frequently synthesize both neuropeptides and classical low–molecular-weight neurotransmitters, challenging the historical interpretation of one-neuron-one-transmitter signaling. Rather than representing biochemical redundancy, coexistence reflects a conserved organizational strategy that expands neural coding capacity through chemical multiplexing. Dual vesicular architecture–small clear vesicles for rapid synaptic transmission and large dense-core vesicles for activity-dependent peptide release–creates stimulus-intensity-dependent recruitment of distinct signaling layers. Classical transmitters primarily mediate millisecond-scale synaptic precision, whereas peptides engage slower G-protein–coupled receptor pathways that modulate excitability, plasticity, gene expression, and neuron–glia interactions. Across mammalian circuits, cotransmission regulates oscillatory coherence, learning and memory, motivational states, endocrine integration, sensory gain control, and autonomic balance. Peptidergic signaling is transcriptionally regulated and dynamically remodeled during development, stress, injury, and disease. Dysregulation contributes to chronic pain, addiction, stress-related disorders, epilepsy, cardiovascular dysfunction, and neurodegeneration. Therefore, neuropeptide-neurotransmitter coexistence constitutes a core computational principle of the nervous system, enabling temporal stratification and adaptive plasticity without expanding anatomical connectivity. Understanding chemical multiplexing is essential for linking molecular dynamics to circuit stability and vulnerability in health and disease.
1 Introduction - from Dale’s principle to molecular multiplexing: reframing chemical neurotransmission
The classical formulation of chemical neurotransmission emerged from early 20th-century physiology. These physiological studies led to the identification of acetylcholine (ACh) by Loewi (1921), noradrenaline (NA) by von Euler (1946), and adrenaline, originally identified as an adrenal hormone by and Takamine (1901), as the first classical neurotransmitters in the nervous system. The concept of chemical neurotransmission crystallized into the widely cited “one neuron-one transmitter” interpretation of Dale’s 1934 lecture (Dale, 1935), later reinforced by electrophysiological analyses from John Carew Eccles and colleagues (Eccles, 1957, 1964). Although historically influential, this conceptual simplification obscured a now-fully recognized central property of neuronal communication that is equally fundamental: most neurons produce and release a cocktail of messengers.
Neuropeptides were identified before their formal designation, even before the idea of chemical signaling was established in physiology (Burbach, 2011). During the 19th century, as experimental life sciences advanced, organ extracts were systematically examined for their effects on physiological systems, and the foundations of endocrinology were established. Compounds such as secretin, insulin, vasopressin (AVP), and oxytocin (OT) were identified as having biological activity in crude extracts, as evidenced by bioassays conducted in whole organisms or organ systems (Oliver and Schäfer, 1895; ; Farini, 1913; von den Velden, 1913). In 1905, the English physiologist Ernest Starling coined the term “hormones” to designate such chemicals. It was only in the 1950s and thereafter that the chemical identities of hormones were clarified; notably, nearly all were found to be short chains of amino acids, specifically peptides. Extensive purification of releasing factors from hypothalamic extracts was conducted, leading to an understanding of their structures in the late 1960s and culminating in the awarding of the Nobel Prize to Roger Guillemin, Andrew Viktor Schally, and Rosalyn Yalow in 19771. Beginning in the late 1950s, Victor Mutt identified numerous novel peptide hormones originating from gastrointestinal organs and, subsequently, from the brain, based on their chemical characteristics (Tatemoto and Mutt, 1980). In parallel with the recognition of peptide hormones, another milestone leading to today’s definition of neuropeptides pertains to neurosecretion. Following early research by Carl Speidel in 1917, Ernst Scharrer introduced the notion of neurosecretion (Scharrer, 1954). The peptides identified were AVP and OT, along with their neurophysins, which were subsequently confirmed by immunocytochemistry. The neurosecretion of peptidergic compounds is nowadays recognized as a crucial element of neuropeptide physiology (Hökfelt et al., 1980a). A last aspect in the history of neuropeptides is the identification of their biological effects on the nervous system. David de Wied was a pioneer in studying the effects of peptide hormones on rat behavior from the 1950s, discovering that corticotropin (ACTH), melanocyte-stimulating hormone (MSH), and AVP influenced brain function and impacted learning and memory processes (De Wied, 1971; De Wied and Versteeg, 1979). In the 1970s, he introduced the term “neuropeptides” to refer to neuroactive peptide hormones and their fragments. Today, NeuroPep 2.0, a database dedicated to annotating neuropeptides and receptors, contains 11,417 unique neuropeptide entries across 924 species (Wang et al., 2024). For those unfamiliar with the topic, Table 1 provides an overview of the major peptidergic neurotransmitter systems in the mammalian nervous system. Further information can be found in a forthcoming encyclopedia entry (Merighi, 2026).
TABLE 1
| Peptidergic system | Main peptides | Gene/precursor | Receptor classes | Coexistence examples | Co-transmission examples |
|---|---|---|---|---|---|
| Opioid | β-Endorphin, enkephalins (Met-, Leu-), DYNs, nociceptin/orphanin FQ (; Kieffer and Gavériaux-Ruff, 2002) | POMC (β-endorphin); PENK (enkephalins); PDYN (DYNs); PNOC (nociceptin) () | μ (MOR), δ (DOR), κ (KOR), NOP/ORL1 (Kieffer and Gavériaux-Ruff, 2002) | Enkephalin co-localizes with GABA in striatopallidal MSNs (Le Moine and Bloch, 1995); DYN with SP in striatonigral neurons () | Arcuate POMC neurons co-release β-endorphin + ACTH (Harno et al., 2018); spinal enkephalinergic interneurons co-release enkephalin + GABA to gate nociception (Todd, 2010) |
| Tachykinin | SP, NKA, NKB, neuropeptide K, neuropeptide γ (Severini et al., 2002) | TAC1 (SP, NKA); TAC3 (NKB) (Severini et al., 2002) | NK1R, NK2R, NK3R (Severini et al., 2002) | SP co-localizes with 5-HT in raphe neurons (Sergeyev et al., 1999); with GABA in cortical interneurons (Jakab et al., 1997); NKB with kisspeptin and DYN (KNDy neurons) (Goodman et al., 2013) | Dorsal root ganglion C-fibers co-release SP + CGRP + glutamate (Russell et al., 2014); KNDy neurons co-release kisspeptin, NKB, DYN to pulse-generate GnRH (Uenoyama et al., 2021) |
| CGRP | α-CGRP, β-CGRP, AM, amylin (Russell et al., 2014) | CALCA (α-CGRP); CALCB (β-CGRP); ADM; IAPP (amylin) (Russell et al., 2014) | CLR/RAMP1 (CGRP-R), CLR/RAMP2 (AM1-R), CLR/RAMP3 (AM2-R), CTR/RAMP (AMY-R) (Russell et al., 2014) | α-CGRP co-localizes with SP in nociceptive primary afferents (Uenoyama et al., 2021), with ACh at the NMJ (Matteoli et al., 1988) | Trigeminal sensory neurons co-release CGRP + SP + glutamate during migraine-associated neurogenic inflammation (Wrobel Goldberg and Silberstein, 2015); NMJ motor terminals co-release ACh + CGRP to modulate receptor clustering (Di Angelantonio et al., 2003) |
| NPY family | NPY, PYY, PP () | NPY; PYY; PPY () | Y1R–Y5R () | NPY co-localizes with NA in locus coeruleus and sympathetic neurons (Illes and Regenold, 1990), with GABA in cortical and hippocampal interneurons (Comeras et al., 2021) | Sympathetic vasoconstrictor terminals co-release NA + NPY (Pernow, 1988); post-synaptic Y1R activation potentiates vasoconstriction (Christiansen et al., 2018); hippocampal NPY/GABA interneurons suppress excitability during high-frequency firing (Magloire et al., 2019) |
| Hypothalamic releasing/ inhibiting peptides | CRH, TRH, GHRH, SST, GnRH, OT, AVP (Russell, 2018) | CRH; TRH; GHRH; SST; GNRH1; OXT; AVP (Russell, 2018) | CRHR1/2, TRHR, GHRHR, SSTR1–5, GnRHR, OXTR, V1aR/V1bR/V2R (Russell, 2018) | CRH co-localizes with AVP in parvocellular PVN neurons (Herman and Tasker, 2016); SST with NPY in cortical interneurons (Herman and Tasker, 2016); OT with DYN in magnocellular neurons (Villar et al., 1990) | PVN parvocellular neurons co-release CRH + AVP synergistically onto pituitary corticotrophs (Itoi et al., 1999); magnocellular OT neurons co-release OT + DYN for autocrine feedback (Hirasawa et al., 2004) |
| VIP/PACAP family | VIP, PACAP-27, PACAP-38, PHI/PHM, Secretin, Glucagon, GLP-1/2, GIP (Vaudry et al., 2009) | VIP; ADCYAP1 (PACAP); SCT; GCG (Vaudry et al., 2009) | VPAC1R, VPAC2R, PAC1R (Vaudry et al., 2009) | VIP co-localizes with ACh in autonomic parasympathetic neurons (Eva et al., 1985); PACAP with catecholamines in adrenal chromaffin cells (Kuri et al., 2009); VIP with GABA in cortical interneurons (VIP + disinhibitory circuits) () | Parasympathetic neurons to salivary glands co-release ACh (vasoconstriction at low frequency) + VIP (vasodilation at high frequency) – classic frequency-dependent co-transmission (Eva et al., 1985); cortical VIP interneurons co-release VIP + GABA to disinhibit pyramidal cells (; Pi et al., 2013) |
| CCK | CCK-8, CCK-33, CCK-58 (Rehfeld, 2017) | CCK (Rehfeld, 2017) | CCK1R (CCK-AR), CCK2R (CCK-BR/gastrin-R) (Rehfeld, 2017) | CCK co-localizes with DA in mesolimbic neurons (Crawley et al., 1984); with GABA in hippocampal basket cells and cortical interneurons (Pelkey et al., 2017) | Ventral tegmental area neurons co-release DA + CCK (Martinez Damonte et al., 2023); CCK potentiates DA signaling via CCK2R (Martinez Damonte et al., 2023); hippocampal CCK + basket cells co-release CCK + GABA for perisomatic inhibition modulation (Freund and Katona, 2007) |
| Galanin | Galanin, galanin-like peptide (GALP), alarin (Lang et al., 2015) | GAL; GALP (Lang et al., 2015) | GALR1, GALR2, GALR3 (Lang et al., 2015) | Galanin co-localizes with ACh in BFCNs (McDonald and Crawley, 1997); with 5-HT in dorsal raphe (Ögren et al., 2007); with NA in locus coeruleus (Caestecker et al., 2025) | BFCNs co-release ACh + galanin (Mufson et al., 2005); GALR activation inhibits ACh release (autoinhibitory loop) (Counts et al., 2006); upregulated in AD, possibly compensatory (Counts et al., 2006) |
| Orexin/ hypocretin | Orexin-A (hypocretin-1), orexin-B (hypocretin-2) (de Lecea et al., 1998) | HCRT (de Lecea et al., 1998) | OX1R (HCRTR1), OX2R (HCRTR2) (de Lecea et al., 1998) | Orexin co-localizes with DYN and glutamate in lateral hypothalamic neurons (Muschamp et al., 2014), with NPTX2 (Reti et al., 2002) | Lateral hypothalamic orexin neurons co-release orexin + DYN + glutamate (Krauth, 2025); glutamate provides fast excitation while orexin sustains arousal (Sakurai, 2007); DYN provides postsynaptic feedback inhibition (Sakurai, 2007) |
| SST | SST-14, SST-28, cortistatin (Patel, 1999) | SST; CORT (cortistatin) (Patel, 1999) | SSTR1–SSTR5 (Patel, 1999) | SST co-localizes with GABA in cortical and hippocampal interneurons (Martinotti cells) (Kecskés et al., 2020); with NPY in hypothalamic neurons () | Cortical Martinotti cells co-release SST + GABA (Wang et al., 2004); SST inhibits glutamate release presynaptically via SSTR, while GABA mediates postsynaptic inhibition – dual suppression of pyramidal output (Kawaguchi and Kubota, 1997) |
| Neurotensin | NT, neuromedin N (Carraway and Leeman, 1973) | NTS (Carraway and Leeman, 1973) | NTS1R, NTS2R, NTS3R/sortilin (Vincent, 1995) | NT co-localizes with DA in mesolimbic/nigrostriatal pathways (Perez-Bonilla et al., 2020); with GABA in striatum (Patel et al., 2024) | Mesolimbic DA neurons co-release DA + NT (); NT potentiates DA-evoked locomotion via NTS1R (); implicated in antipsychotic-like effects (Goldstein and Deutch, 1992) |
| Natriuretic peptides | ANP (ANF), BNP, CNP, DNP (Potter et al., 2009) | NPPA (ANP); NPPB (BNP); NPPC (CNP) (Potter et al., 2009) | NPR-A (GC-A), NPR-B (GC-B), NPR-C (Potter et al., 2009) | NPR-C co-localizes with glutamate in hippocampal interneurons (Decker et al., 2009) | Hippocampal interneurons co-release CNP + glutamate (Decker et al., 2009); CNP acts via NPR-B to modulate synaptic plasticity (Decker et al., 2010); cardiovascular neurons co-release ANP + catecholamines (Tota et al., 2010) |
| Melanocortins | α-MSH, β-MSH, γ-MSH, ACTH, β-endorphin (Mercer et al., 2013) | POMC (Mercer et al., 2013) | MC1R–MC5R (Mercer et al., 2013) | POMC neurons in the arcuate nucleus co-express α-MSH, ACTH, β-endorphin (Cowley et al., 2001); co-localize with cocaine- and CART (Lau et al., 2018) | Arcuate POMC neurons co-release α-MSH + β-endorphin + CART (Cowley et al., 2001); α-MSH → MC4R for anorexia; β-endorphin → MOR for rewards modulation – divergent co-transmission within single neurons (Mercer et al., 2013) |
| PACAP | PACAP-27, PACAP-38 (Sherwood et al., 2000) | ADCYAP1 (Sherwood et al., 2000) | PAC1R, VPAC1R, VPAC2R (Sherwood et al., 2000) | PACAP co-localizes with glutamate in the retinohypothalamic tract (Hannibal et al., 2000), with catecholamines in adrenal medulla and autonomic ganglia (Kuri et al., 2009) | Retinohypothalamic tract fibers co-release PACAP + glutamate onto SCN (Hannibal et al., 2000); glutamate mediates acute phase shift; PACAP provides sustained photic entrainment – functionally distinct roles at the same synapse (Hannibal et al., 2000) |
Overview of major peptidergic neurotransmitter systems.
Key peptides, biosynthetic precursor genes, receptor classes, patterns of coexistence with classical transmitters, and representative examples of co-transmission are listed. 5-HT, serotonin; ACh, acetylcholine; ACTH, adrenocorticotropic hormone; AM, adrenomedullin; ANP/ANF, atrial natriuretic peptide/factor; AVP, arginine vasopressin; BFCNs, basal forebrain cholinergic neurons; BNP, brain natriuretic peptide; CART, cocaine- and amphetamine-regulated transcript; CCK, cholecystokinin; CGRP, calcitonin gene-related peptide; CNP, C-type natriuretic peptide; CRH, corticotropin-releasing hormone; DA, dopamine; DNP, dendroaspis natriuretic peptide; DOR, δ-opioid receptor; DYN, dynorphin; GABA, γ-aminobutyric acid; GIP, glucose-dependent insulinotropic polypeptide; GLP, glucagon-like peptide; GnRH, gonadotropin-releasing hormone; GHRH, growth hormone-releasing hormone; KNDy, Kisspeptin, Neurokinin B, and Dynorphin; KOR, κ-opioid receptor; MC4R, melanocortin 4 receptor; MOR, μ-opioid receptor; MSH, melanocyte-stimulating hormone; MSNs, medium spiny neurons; NA, noradrenaline; NKA, neurokinin A; NKB, neurokinin B; NMJ, neuromuscular junction; NOP, nociceptin/orphanin FQ receptor; NPR-B, natriuretic peptide receptor B; NPTX2, neuronal pentraxin 2; NPY, neuropeptide Y; NT, neurotensin; OT, oxytocin; PACAP, pituitary adenylate cyclase-activating polypeptide; PDYN, prodynorphin; PENK, proenkephalin; PHI/PHM, peptide histidine isoleucine/methionine; POMC, pro-opiomelanocortin; PNOC, pronociceptin; PP, pancreatic polypeptide; PVN, paraventricular nucleus; PYY, peptide YY; SCN, suprachiasmatic nucleus; SP, substance P; SST, somatostatin; TRH, thyrotropin-releasing hormone; VIP, vasoactive intestinal peptide.
The discovery that neuropeptides coexist with classical low–molecular-weight neurotransmitters transformed our understanding of synaptic organization. Seminal neuroanatomical and immunocytochemical studies by Tomas Hökfelt and collaborators demonstrated that peptides are not confined to specialized neurosecretory cells but are widely distributed across central and peripheral neuronal populations (Hökfelt et al., 1980a,b; Lundberg et al., 1980; Lundberg and Hökfelt, 1983). These observations challenged the rigid interpretation of Dale’s principle. They introduced a new framework built on three related but distinct concepts: coexistence (multiple transmitters within a single neuron), costorage (multiple transmitters within a single vesicular compartment), and cotransmission (activity-dependent corelease).
The coexistence of different transmitters in a single neuron is now regarded as the rule rather than an exception. In most cases, coexistence concerns neuropeptides and classical transmitters. Neurons that synthesize neuropeptides and classical transmitters operate through two spatially and kinetically distinct vesicular systems (Merighi, 2002, 2018). Small clear vesicles (SCVs) store glutamate (Merighi et al., 1991), GABA (Merighi et al., 1989a), ACh (Brown, 2006), monoamines (Mulvihill, 2019), and purines (Burnstock, 1983, 2007), and primarily support ultrafast, point-to-point synaptic transmission. In contrast, large dense-core vesicles (LDCVs) contain neuropeptides (Salio et al., 2006) and, frequently, high-molecular-weight signaling proteins, such as certain neurotrophic factors (Salio et al., 2007), and require sustained or high-frequency stimulation for exocytosis. This molecular segregation is not incidental; it constitutes a regulatory architecture that enables stimulus–intensity–dependent recruitment of distinct chemical signals (Figures 1, 2). A further element of regulation lies in the possibility that both individual SCVs and LDCVs store more than a single messenger molecule. Costorage in LDCVs is widely accepted nowadays, whereas SCVs remain an open issue (Mondoloni and Mameli, 2022). Electrophysiological observations have demonstrated co-release of GABA and glutamate at basal ganglia-to-habenula synapses (Shabel et al., 2014; Kim et al., 2022). Yet, an ultrastructural study suggested that the two amino acid transmitters are stored in different SCVs based on the localization of the respective vesicular transporters (Root et al., 2018).
FIGURE 1
FIGURE 2
As a consequence of coexistence and/or costorage within a single neuron, cotransmission may occur. The existence of low- and high-molecular-weight neuromessengers introduces temporal coding into neural communication (Merighi et al., 1989b; Merighi, 2002, 2009, 2017). As mentioned, low-molecular-weight classical transmitters mediate fast synaptic transmission. The latter occurs after activation of ionotropic receptors with effects on the millisecond scale. Yet, these transmitters also act through metabotropic G-protein–coupled receptors (GPCRs) that signal on a slower time scale and often function as autoreceptors, providing negative feedback and thus modulating synaptic responses (Bowery et al., 2002; Fredholm et al., 2005; ; Gilsbach and Hein, 2008; Niswender and Conn, 2010; ). High-molecular-weight neuropeptides primarily act through GPCRs (Vaudry and Seong, 2014), generate modulatory responses spanning seconds to minutes, and may initiate transcriptional programs lasting hours. In addition, some of the larger molecules that can be cargoed in LDCVs, i.e., brain-derived neurotrophic factor (BDNF) () and glial-derived neurotrophic factor (GDNF) (Merighi, 2016; Ferrini et al., 2021), signal through receptor tyrosine kinases (RTKs). Thus, cotransmission represents a form of biochemical multiplexing, enabling a single neuron to encode both fast synaptic accuracy and slow network modulation without necessitating structural reconfiguration (Nusbaum et al., 2017; Svensson et al., 2019). Notably, recent research in Drosophila has demonstrated that posttranscriptional regulation of fast transmitter cotransmission also provides a mechanism for the reversible tuning of neuronal output (Chen et al., 2023). These authors have, in fact, demonstrated that many glutamatergic and GABAergic cells also transcribe cholinergic genes but fail to accumulate cholinergic effector proteins, and undergo transient translation of cholinergic proteins, indicating that suppression of cotransmission is actively modulated. Evolutionary data suggest that this arrangement is not superfluous but rather represents distinct signaling systems. In primitive metazoans, neuropeptides probably emerged before fast amino acid transmitters and functioned through diffuse modulatory networks (Jékely, 2021). Later in evolution, the emergence of rapid synaptic transmission increased the speed of pre-existing modulatory frameworks. More recent nervous systems, therefore, integrate ancient peptide-based communication with high-fidelity point-to-point transmission, preserving both flexibility and computational efficiency. Beyond its molecular elegance, coexistence carries profound functional consequences. Peptide–neurotransmitter interactions regulate synaptic plasticity, oscillatory dynamics, motivational states, endocrine rhythms, sensory gain control, and autonomic output (). However, dysregulation of cotransmission contributes to network instability, chronic pain, addiction, and stress-related disorders, to name a few examples. The dual-transmitter architecture is therefore not merely a biochemical curiosity but a central determinant of neural computation and adaptability.
This review synthesizes current knowledge of how neuropeptides and classical neurotransmitters are organized at the molecular level, how they are released, how they interact within systems, their evolutionary history, and their roles in disease. These features support the idea that cotransmission is a fundamental way the nervous system processes information, expanding its ability to encode it through multiple chemicals in both time and space.
2 Molecular architecture of dual transmitter systems
The coexistence of neuropeptides and classical neurotransmitters is not simply a matter of coexpression; it is part of a highly organized molecular architecture that segregates synthesis, packaging, trafficking, and release into parallel but interacting pathways. This dual-system organization provides the structural basis for activity-dependent chemical multiplexing.
2.1 Neuropeptide biosynthesis, LDCV biogenesis, and termination of peptidergic neurotransmission
The synthesis of neuropeptides involves a series of biochemical steps that begin with large precursor proteins. These prepropeptides are produced from specific genes and translated on the rough endoplasmic reticulum (Sossin and Scheller, 1991). After translation, a second step involves the formation of propeptides upon removal of the signal peptide. These propeptides then undergo several changes, including endoproteolytic cleavage, carboxypeptidase trimming, amidation, sulfation, and glycosylation (Seidah and Chrétien, 1992; Hook et al., 2008).
Unlike classical transmitters, which are produced locally in nerve terminals, transcription of neuropeptide mRNAs in the neuronal soma controls neuropeptide production in response to activity levels (Figure 1). Transcriptional control is mediated by cyclic AMP response element-binding protein (CREB) and c-Fos (Chowdhury et al., 2023). Increases in intracellular Ca2+ and cAMP activate these two transcription factors. Control of gene expression allows neurons to adjust their peptide content in response to conditions such as developmental stage, injury, stress, or prolonged network stimulation. Therefore, the plasticity of peptidergic neurons enables a broader functional scope of cotransmission. LDCV biogenesis requires careful cargo collection and sorting. The ultrastructure of mature LDCVs has been widely investigated using electron microscopy. Typically, LDCVs measure 100–500 nm in diameter and contain an electron-dense core composed of packed peptides and associated proteins (Merighi et al., 1989a). Proteins of the granin family contribute to the condensation of cargo inside LDCV, while additional conserved proteins–including the endosome-associated recycling protein (EARP) complex, EARP-interacting protein 1 (EIPR-1), and conserved coiled-coil protein 1 (CCCP-1)–participate in vesicle maturation and membrane trafficking (Winkler et al., 1991; Winkler and Fischer-Colbrie, 1998; ). Importantly, LDCVs frequently contain multiple peptides/high–molecular-weight signaling molecules. Ultrastructural investigations revealed that these costored messengers can be present in specific stoichiometric proportions, suggesting a coordinated packaging process rather than random aggregation (Salio et al., 2007). The question of whether different groups of LDCVs exhibit distinct peptide compositions remains under investigation, and answering it would be important for clarifying several functional aspects of LDCV biology. The movement of LDCVs from the cell body to axon terminals or dendrites depends on microtubules and is primarily mediated by kinesin-3 (KIF1A) (Hirokawa et al., 2010) and dynein–dynactin (Waterman-Storer et al., 1997) motor complexes. Whereas anterograde axonal transport depends on KIF1A, the existence of about 50% dendrites with mixed polarity in rodents (Tas et al., 2017) permits, in principle, both kinesin and dynein to carry LDCVs distally. Vesicle transport is bidirectional and dynamic, with periods of pausing and varying movement lengths (Kwinter et al., 2009). Because peptide replenishment requires synthesis in the cell body and long-distance transport, replacing them after they are released is relatively slow (Wong et al., 2012).
Peptidergic signaling is ended through several overlapping mechanisms. These mechanisms are much slower than those that terminate fast neurotransmission mediated by classical transmitters. The first and most immediate factor is the simple diffusion from the release site. Because neuropeptides are often released extrasynaptically and act via volume transmission (Zoli et al., 1999; Vizi et al., 2004; Fuxe and Borroto-Escuela, 2016), their concentration at target receptors decays as they diffuse through the extracellular space. Extracellular proteolytic degradation is the primary mechanism for terminating neuropeptide signals (Defea et al., 2000); other mechanisms involve internalization of the peptide or peptide-receptor complex, followed by intracellular degradation (). The key extracellular peptidases include neprilysin (neutral endopeptidase/enkephalinase, NEP), angiotensin-converting enzyme (ACE), dipeptidyl peptidase 4 (DPP4), aminopeptidases, and endopeptidase 24.15 (neurolysin).
Neutral endopeptidase/enkephalinase is the best-characterized neuropeptidase. It degrades substance P (SP) (Skidgel et al., 1984), as well as enkephalin (Roques et al., 1982), bradykinin (Campbell, 2018), calcitonin gene-related peptide (CGRP) (Krämer et al., 2009), neurotensin (NT) (Skidgel and Erdös, 2004), and OT (Riley et al., 1995), among others. ACE (Skidgel and Erdös, 2004), DPP4 (Canneva et al., 2015), aminopeptidases (Ramírez et al., 2011), and endopeptidase 24.15 (Dahms and Mentlein, 1992) also contribute in a peptide- and context-dependent manner. The bioactivity of neuropeptide Y (NPY) is either N-terminal modulation by DPP4-like enzymes with respect to receptor selectivity or proteolytic degradation by NEP or meprins, thereby abrogating signal transduction (Wagner et al., 2015). Enzymatic degradation via extracellular peptidases rather than by reuptake mechanisms results in cerebral half-lives for neuropeptides such as AVP and OT of approximately 20 min in cerebrospinal fluid (Mens et al., 1983), whereas CGRP has a half-life of 7 min in plasma (Kraenzlin et al., 1985), but there are no data in extracellular fluids. Finally, because most neuropeptide receptors are GPCRs, the signaling cascade may also be terminated at the receptor level. Termination of neuropeptide signaling at this level may occur through uncoupling of receptors from heterotrimeric G proteins and receptor endocytosis (Defea et al., 2000). Specifically, agonist-occupied receptors are phosphorylated by G-protein-coupled receptor kinases (GRKs), which recruit β-arrestins. Steric binding by β-arrestin interferes with further G protein coupling, leading to desensitization of G protein-dependent signaling (Grady et al., 1996; Marvizon et al., 1999). Notably, β-arrestin-dependent desensitization and internalization of receptors leads to suppression of GPCR signaling for several hours.
2.2 Classical neurotransmitter synthesis and small synaptic vesicle structure
Classical neurotransmitters–ACh, amino acids, monoamines, and purines–are synthesized locally within neuronal processes, mainly at presynaptic terminals. Their biosynthetic enzymes and vesicular transporters are advantageously positioned at these sites to ensure rapid supply and high-frequency release from 40 to 60 nm SCVs, which store these transmitters at high concentration (Fei and Krantz, 2009). Vesicular loading depends on dedicated transporters (e.g., vesicular glutamate transporters - VGLUTs - for glutamate, vesicular GABA transporter - VGAT - for GABA/glycine, vesicular monoamine transporter 2 - VMAT2 - for monoamines, vesicular acetylcholine transporter - VAChT - for ACh) driven by a proton electrochemical gradient (Onoa et al., 2010). SCVs are clustered at active zones and tethered near voltage-gated Ca2+ channels, ensuring nanodomain coupling between Ca2+ influx and vesicle fusion (Eggermann et al., 2011). The release of SCVs depends on the SNAP receptor (SNARE) complex. The complex comprises proteins, including vesicular synaptobrevins (v-SNAREs) and syntaxin/SNAP-25 (soluble NSF attachment protein 25) on target membranes (Südhof, 2008, 2012). Synaptotagmin primarily senses Ca2+. This molecular complex empowers exocytosis within milliseconds of depolarization. Importantly, SCVs are rapidly retrieved via clathrin-mediated endocytosis or ultrafast endocytic pathways, refilled, and recycled to terminate fast signaling (Watanabe et al., 2014). This very efficient cycle supports continued high-frequency transmission without requiring transcriptional upregulation. The tight spatial localization of SCVs to active zones safeguards point-to-point synaptic specificity. Classical transmitters therefore operate with high temporal and spatial precision, providing the fast computational backbone of neural circuits.
2.3 Vesicular segregation as a regulatory principle
The isolation of neuropeptides and classical transmitters into distinct vesicle classes is not redundant–it is mechanistically strategic. The core understanding is that the physical separation of neuropeptides into LDCVs and classical transmitters into SCVs is not an evolutionary accident or mere anatomical tidiness – it encodes distinct release rules, spatial ranges, and computational functions that would be mutually incompatible if co-packaged. Vesicular separation is mechanistically strategic because the vesicle type simultaneously determines three separable yet interacting properties: release threshold, spatial geometry, and downstream receptor coupling. SCVs and LDCVs, in fact, not only differ in size and ultrastructure, cargo composition, but also in Ca2+ sensitivity, release kinetics, recycling capacity, and spatial release domains. In addition, SCV fusion requires a high concentration of Ca2+ in microdomains near voltage-operated channels (Parekh, 2008). On the other hand, LDCV exocytosis normally requires higher and more sustained intracellular Ca2+ elevations, as well as repetitive or high-frequency stimulation (Cifuentes et al., 2008; Ludwig and Stern, 2015). Consequently, peptide release typically occurs after classical transmission has already initiated. As mentioned, LDCVs are not only located at active zones. Therefore, these vesicles can be released via exocytosis at either perisynaptic or extrasynaptic sites, thereby facilitating volume transmission (Zoli et al., 1999; Vizi et al., 2004; Fuxe and Borroto-Escuela, 2016). Thus, the capacity of LDCVs to be distributed across various neuronal compartments and released from multiple sites, rather than being confined to synapses, allows neuropeptides to exert influence on a broader range of cells, including those located at significant distances from the initial release site. Furthermore, the disparate recycling rates of these two messenger types contribute to their divergence (Eiden et al., 2022; Hevesi et al., 2025). Whereas SCVs are rapidly endocytosed for recycling at terminals, LDCVs are not recycled following exocytosis; thus, replenishing the LDCV pool requires de novo synthesis and transport of their contents. Therefore, peptide signaling is discontinuous and state-dependent rather than continuously sustainable. Together, these properties create a graded signaling architecture in which neurons can operate both fast synaptic transmission for precision and slow modulatory transmission for context integration. Vesicular segregation, therefore, acts as a built-in regulatory mechanism that converts stimulus intensity and duration into chemically distinct outputs (Cárdenas and Marengo, 2016). Mixing vesicle cargoes would not merely blur the signals – it would destroy the frequency-dependent, spatially graded, timescale-separated logic that makes co-transmitting neurons capable of encoding both fast information and slow states. Two examples of the strategic importance of vesicle separation are the co-release of NPY and GABA in hippocampal interneurons (van den Pol, 2012) and SP and glutamate in dorsal horn nociceptive circuits (De Koninck and Henry, 1991; Woolf and Salter, 2000).
In certain GABAergic hippocampal interneurons (basket cells, Schaffer collateral-associated cells), GABA is localized in SCVs and NPY in LDCVs. The strategic separation here operates at the level of stimulation frequency. A single action potential or a low-frequency train (<5 Hz) raises intraterminal Ca2+ to ∼1–10 μM at the active zone, which is sufficient to trigger SNARE-mediated fusion of docked SSVs via synaptotagmin-1. GABA is released with sub-millisecond latency into the synaptic cleft, activates postsynaptic GABAA receptors, and produces rapid Cl–-mediated inhibition. LDCVs, by contrast, are physically excluded from the active zone. They are located ≥100–300 nm away, where local Ca2+ concentrations never reach the levels required for fusion machinery, which consists of synaptotagmin-7 or -9. Only during high-frequency burst firing (≥10–20 Hz, as occurs during theta oscillations or intense sensory drive) does global Ca2+ rise sufficiently across the terminal to trigger LCDV exocytosis. NPY is then released extrasynaptically, diffuses by volume transmission over hundreds of μm, and acts via Gi-coupled Y1/Y2 receptors to suppress adenylyl cyclase, reduce presynaptic Ca2+ currents, and hyperpolarize postsynaptic neurons via G protein-coupled inward rectifier K+ (GIRK) channels. The strategic consequence is a two-layer inhibitory system with intrinsic frequency-detection: basal activity is handled by GABA alone (fast, local, restorable); pathological hyperactivity recruits NPY as a second, longer-lasting, spatially broader brake, providing a form of gain control that SCV-based signaling alone could never achieve. Merging NPY into SSVs would strip it of this frequency gating and eliminate the computational distinction.
Primary afferent C-fibers entering the dorsal horn of the spinal cord co-contain glutamate in SCVs and SP + CGRP in LDCVs. This pairing is the canonical model for the distinction between acute and persistent pain signaling. With innocuous or mild noxious stimulation, C-fibers fire at low frequency. SCV-glutamate release activates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on projection neurons, producing fast EPSPs that encode stimulus intensity in real time, thereby giving rise to the acute, sharp, well-localized component of pain. The Mg2+ block keeps NMDA receptors silent. During intense, sustained, or repeated noxious stimulation (high-frequency C-fiber burst), LDCVs are recruited. SP is released from extrasynaptic sites and binds NK1 receptors (NK1R - Gq-coupled) on postsynaptic neurons and on astrocytes. NK1R activation raises Ca2+ via inositol triphosphate (IP3), activates protein kinase C (PKC), which phosphorylates and relieves Mg2+ block of NMDA receptors. This triggers a phenomenon called wind-up, with progressive amplification of postsynaptic responses that leads to central sensitization. CGRP simultaneously dilates blood vessels and activates glia. The entire mechanism is mechanistically strategic because the two signals serve qualitatively different computational roles on different timescales: glutamate/AMPA encodes acute pain; SP/NK1R encodes long-lasting pain and reconfigures the circuit for heightened sensitivity. Co-packaging these messengers in SCVs would either fire SP at every stimulus (thereby destroying its threshold meaning) or require a separate release mechanism for each (impossible within a single vesicle class).
2.4 Is the SCV/LDCV dicothomy absolute?
Co-storage of low-molecular-weight transmitters and neuropeptides within the same SCV is poorly established and considered atypical. In human sympathetic neurons of the lumbar ganglia, an electron microscopic study reported the concurrent presence of somatostatin (SOM) and NA (as detected by tyrosine hydroxylase immunostaining) in 40–60 nm vesicles (Järvi et al., 1987). However, we did not find other data in the literature supporting this observation. Conversely, LDCVs can store a low-molecular-weight neurotransmitter together with a neuropeptide. In sympathetic nerve homogenates and after immunocytochemical localization, NA was found to be stored in both SCVs and LDCVs, the latter of which also contain NPY (Fried et al., 1986; De Potter et al., 1987) or enkephalin (Fried et al., 1986; De Potter et al., 1987). These observations are well-documented and constitute the strongest example of the co-storage of a low-molecular-weight neurotransmitter and a neuropeptide within a single LDCV. Thus, the dichotomy between SCVs and LDCVs in terms of neurotransmitter content is not absolute, but the above observations likely represent remarkable exceptions to a general rule.
2.5 Costorage and molecular complexity of LDCVs
The possibility that several neuropeptides are costored in individual LDCVs adds further complexity to our understanding of neuropeptide signaling. Numerous peptides within a single LDCV can be released concurrently; however, evidence indicates that selective or partial release can occur via mechanisms such as kiss-and-run fusion (; Rutter and Tsuboi, 2004; Zhang et al., 2011). The occurrence of flexible peptide release from the same vesicle under physiological and/or pathological conditions remains controversial. Peptides and neurotrophic factors coexist within LDCVs of a subset of primary afferent neurons (Merighi et al., 1989b; Merighi, 2002; Salio et al., 2007). These neurons give rise to C-fibers projecting to the spinal cord lamina II (Uenoyama et al., 2021). These colocalized molecules integrate rapid glutamate transmission (the main neurotransmitter of the C-fibers) with sustained modulation, contributing to central sensitization in chronic pain states (Merighi et al., 2008; Uenoyama et al., 2021). The possibility of distinct LDCV subtypes with distinct neurochemical profiles within the same neuron remains an open question. Advanced imaging, single-vesicle proteomics, and super-resolution microscopy may clarify whether vesicular identity indeed occurs and encodes functional specialization.
The dual-transmitter neuron is therefore built upon two partially independent but convergent secretory systems, a fast, locally recyclable synaptic machinery optimized for speed and fidelity, and a slower, gene-regulated system optimized for modulatory scope and plasticity. This architectural arrangement provides the mechanistic foundation for the temporal stratification and operational models of cotransmission discussed in the following section (Hnasko and Edwards, 2012).
3 Release dynamics and temporal stratification: from synaptic precision to network modulation
The previously discussed dual vesicular architecture underpins cotransmission. Its functional significance is apparent in release dynamics, wherein fluctuations in Ca2+ sensitivity, vesicle positioning, and recycling kinetics convert stimulus patterns into chemically stratified outputs. Consequently, neurons function as activity-dependent multiplexers, converting firing frequency and duration into qualitatively distinct signaling regimes.
3.1 Differential Ca2+ thresholds and vesicle recruitment
As mentioned, SCVs are closely associated with voltage-gated Ca2+ channels at active zones, where localized Ca2+ increases initiate rapid exocytosis. A single action potential usually triggers fusion, thereby facilitating synaptic transmission on the millisecond timescale (Medeiros et al., 2024). Conversely, LDCVs are frequently located away from active zones, requiring greater cytosolic Ca2+ increases for their exocytosis (Voets et al., 2001). The likelihood of their fusion is augmented by high-frequency firing, burst activity, extended depolarization, metabolic stress, and neuromodulatory priming (van den Pol, 2012). Because LDCV release depends on global Ca2+ accumulation rather than nanodomain coupling, peptide exocytosis typically occurs after classical transmitter release. This temporal sequence establishes a stimulus-intensity–dependent hierarchy: low activity elicits fast synaptic transmission alone, whereas sustained activity recruits peptidergic signaling. This graded recruitment is evident in multiple systems, including sympathetic neurons exhibiting adenosine 5′-triphosphate (ATP) → NA → NPY triphasic output (Cannon et al., 1986; Svensson et al., 2019), and primary sensory afferents releasing glutamate at low frequency but co-releasing SP and CGRP during persistent stimulation (Latremoliere and Woolf, 2009). Therefore, the movement of Ca2+ ions is pivotal to convert electrical patterns into layered chemical signals.
3.2 Spatial separation: point-to-point versus volume transmission
Classical neurotransmitters usually act on receptors located on nearby post- or presynaptic membranes. At high local concentrations, they activate post- or pre-synaptic receptors. These receptors respond quickly but are rapidly inactivated by desensitization, internalization (endocytosis), or antagonist blockade (Brodal, 2016). Therefore, the geometry and molecular assembly of the synapse enforce spatial specificity and limit diffusion (Freche et al., 2011). Neuropeptides released from LDCVs frequently act extrasynaptically. Released peptides can diffuse over tens to hundreds of micrometers, affecting groups of neurons beyond the immediate synaptic connection. This process mainly activates GPCRs located near or distant from the bouton of release (Özçete et al., 2024). This process–often termed volume transmission–allows state-dependent modulation of circuit excitability, synaptic plasticity thresholds, and oscillatory coherence. Importantly, spatial divergence does not imply functional independence. Peptides often also influence the synapses from which they are released. They act presynaptically, controlling Ca2+ influx into the terminal, or postsynaptically, modulating receptor phosphorylation (Fröhlich, 2016). Consequently, volume transmission can also exert a feedback effect on point-to-point signaling, thereby altering circuit gain.
3.3 Chronological layering of neural signaling
Coexistence of classical transmitters in SCVs and neuropeptides in LDCVs endows individual synapses with a frequency-gated, dual-timescale output that integrates phasic ionotropic signaling with sustained metabotropic modulation. The fast (milliseconds) response occurs after ionotropic receptor activation, leading to rapid depolarization or inhibition. This initial response encodes precise spike timing and synaptic integration (Bucher and Goaillard, 2011). A second temporally intermediate response follows (seconds to minutes) during which peptide-activated GPCRs influence ion channel activity, the release of intracellular Ca2+, kinase cascades, and an array of metabolic processes depending on the type of peptide and the context of activation (Lohse et al., 2014; Culhane et al., 2022). As a consequence, excitability, short-term plasticity, and network synchrony are regulated. Finally, sustained peptide signaling, which occurs over minutes to hours, can activate transcription factors like CREB (Montminy et al., 1990). Transcription factor activation, in turn, causes changes in gene expression that alter synaptic structure and the types of receptors expressed at synapses. This third temporal layer links transient activity to long-term alterations in brain function. Therefore, the timing of cotransmission extends a neuron’s influence beyond immediate electrical signals, leading to lasting structural changes (Vaaga et al., 2014; Monday et al., 2018). Remarkably, within this general framework, peptides are not redundant and convey information about the activity’s strength and duration.
3.4 Neuropeptide GPCRs
As mentioned, neuropeptides act by activating specific cell-membrane receptors that are members of the GPCR superfamily, thereby stimulating downstream protein kinase signaling pathways and ultimately altering gene expression. The vast majority of the neuropeptides described to date act through GPCRs (Burbach, 2010). Table 2 lists the main types of GCPRs activated by the most widely investigated neuropeptides. It is worth noting that peptide GPCRs are not only expressed postsynaptically (as depicted for simplicity in Figure 3). Presynaptic autoreceptors are activated by the same neuropeptide produced in the nerve terminal, thereby regulating intrasynaptic feedback and influencing neurotransmission at adjacent synapses. G protein-coupled autoreceptors on both pre- and postsynaptic cells protect against overstimulation by releasing G protein βγ subunits, which activate GIRK channels postsynaptically and block voltage-activated calcium channels presynaptically. The Gβγ subunits can directly engage with SNARE exocytotic machinery to inhibit release ().
TABLE 2
| Neuropeptides | GPCRs | G protein | Cellular mechanisms | Main functions | References |
|---|---|---|---|---|---|
| Opioid peptides | μ, δ, κ Class A GPCRs | Gi/o (inhibitory) | Receptors transduce extracellular messages using Gα and Gβγ subunits, MAPK, and arrestin signaling pathways | CNS: Pain, mood, rewards mechanisms PNS: modulation of nociception, peripheral algesia. | Reeves et al., 2022; Dahliwal and Gupta, 2023 |
| Tachykinins (SP, NKA) | NK1 Class A GPCR | Gq/Gs (activatory) | SP increases both IP and cAMP, second messengers downstream of Gq- and Gs-mediated signaling pathways, respectively. SP released from primary afferent fibers during inflammation upregulates NK1 receptors in dorsal horn neurons, which control the expression of cytokines, chemokines, and transcription factors such as NF-κB. NKA signals potently via Gq but has reduced Gs-stimulatory activity. | CNS: Pain, mood, nausea PNS: Gut motility, inflammation (skin, gastrointestinal tract, respiratory tract) | Martinez et al., 2015; Lang et al., 2020; De Zoysa et al., 2026; Zhang et al., 2026 |
| CGRP | CLR/RAMP1 heterodimer Class B GPCR | Gs (activatory) | Dimerization of CLR with RAMP1 shows the highest affinity for CGRP | CNS: Central sensitization PNS: Vasodilation, migraine | Hay and Walker, 2017; Gingell et al., 2019 |
| NPY, PYY, PP | Y1, Y2, Y4, Y5, and Y6 Class A GPCRs | Gi/o (inhibitory) | Regulation of adenylyl cyclase, activation of MAPK, regulation of intracellular Ca2+ concentrations, and activation of G protein-coupled GIRK channels | CNS: Anxiety, feeding, cognition. Y1 receptors modulate cell activity postsynaptically, whereas Y2 receptors function presynaptically as autoreceptors and heteroreceptors, regulating NPY and co-expressed neurotransmitter release. PNS: Vasoconstriction, sympathetic tone, pain. N-terminal cleaved NPY variants primarily mediate angiogenesis and neurotransmitter release inhibition through Y2. | Marcos and Coveñas, 2022; Nelson et al., 2024; Singanwad et al., 2025 |
| VIP PACAP family | VPAC1, VPAC2 (bind both peptides) PAC1 (only binds PACAP) Class B GPCRs | Gs (activatory), Gq (activatory), or Gi (inhibitory) | Primarily coupled to adenylate cyclase via Gs. Other pathways are activated via βγ subunits and by alternative coupling to Gi and Gq. | CNS: Circadian rhythm, neuroprotection PNS: Immune modulation, gut motility | Hirabayashi et al., 2018; Tasma and Hay, 2025 |
Main types of GPCRs activated by neuropeptides.
cAMP, cyclic adenosine monophosphate; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; CNS, central nervous system; GIRK, G protein-coupled inwardly rectifying potassium; GPCRs, G protein coupled receptors; IP, inositol phosphate; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NKA, neurokinin A; NPY, neuropeptide Y; PAC1, pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP, pituitary adenylate cyclase-activating polypeptide; PNS, peripheral nervous system; PP, pancreatic polypeptide; PYY, Peptide YY; RAMP1, receptor activity modifying protein 1; SP, substance P; VIP, vasointestinal polipeptide; VPAC, vasoactive intestinal peptide receptors; Y, NPY receptors.
FIGURE 3
3.5 Operational models of cotransmission
Based on temporal dynamics and receptor expression, four operational models can be described (Figure 3).
In the so-called hierarchical model, classical transmitters are the main signaling molecules (Svensson et al., 2019). They mediate fast point-to-point signaling upon the arrival of every action potential. Neuropeptides serve as amplifiers or stabilizers of ionotropic transmission, being released from LDCVs exclusively under conditions of intense or repetitive presynaptic activity above a firing-rate threshold that cannot be met by SCV-mediated signaling alone (Vaaga et al., 2014). The main limitation of this model is its unidirectionality, i.e., it does not account for cases in which peptide signaling preconditions or gates the classical transmitter’s efficacy, nor for tonic peptide release. This pattern is often seen in circuits that respond to stressful situations, such as nociceptive circuits (Liu and Sandkühler, 1995), where antibody microprobe measurements in the dorsal horn showed that SP appears extracellularly only during high-intensity nociceptive bursts, whereas glutamate signals are present at every stimulus (Duggan and Furmidge, 1994). Similarly, in sympathetic fibers, low-frequency stimulation releases only NA, whereas high-frequency bursts additionally release NPY, further increasing vasoconstriction (Lundberg and Hökfelt, 1983). As a last example, in cholecystokinin (CCK) immunoreactive basket cells, GABA release is asynchronous throughout, but CCK modulation of network oscillations emerges only during sustained interneuron recruitment (Hefft and Jonas, 2005). According to this model, traditional neurotransmitters and neuropeptides may also affect different domains within a single neuron (e.g., the axon and dendrites) or across different neurons and neuron types (Neuhofer and Kalivas, 2023). In hypothalamic neurons, peptide release from dendrites can occur independently of the more conventional axonal transmission, leading to differences in how signals are sent, depending on the state of neuron activation (Landry et al., 2003; Ludwig et al., 2016).
In parallel mode, co-released messengers enable a single neuron to address two distinct downstream circuits simultaneously by acting on the same cell that expresses different receptor types, or on separate cell populations that express different receptors. The two signals don’t have to necessarily interact. Bona fide, pure parallelism is most likely uncommon. A certain amount of local crosstalk is practically inevitable because LDCVs and SSVs are often released from the same terminal, making it likely that messengers interact in accordance with the hierarchical or integrated models. Yet, three examples of this type of interaction are given below. Spinal cord motor neurons co-release ACh and CGRP; the former acts on skeletal muscle nicotinic receptors and the latter on vascular smooth muscle CGRP receptors (Zaidi et al., 1987). In this case, the two messengers act on completely separate effector systems, with no cross-talk. Yet CGRP positively modulates synaptic transmission at the neuromuscular junction by locally inhibiting acetylcholinesterase expression (Rossi et al., 2003). In the crustacean stomatogastric ganglion, proctolin, an arthropod neuropeptide, and GABA from the same neuron activate entirely different postsynaptic cells, reconfiguring distinct circuit elements in parallel (Nusbaum and Blitz, 2012). Hypothalamic agouti-related peptide/protein (AgRP) neurons co-release GABA, AgRP, and NPY onto three distinct types of receptors, each expressed on non-overlapping target neuronal populations in the arcuate nucleus–paraventricular nucleus circuit ().
In the conditional model, peptide release is activated only under specific physiological or pathological conditions, such as metabolic state, hormonal status, stress, and disease. As a limitation of this model, one has to consider that the mechanistic linkage between the state variable (e.g., a circulating hormone) and the LDCV release machinery is often only partially characterized. It is unclear in many systems whether state modifies release probability per se, vesicle pool composition, or postsynaptic receptor expression, as these mechanisms produce identical phenomenology but rely on very different cellular events. As an invertebrate example, in C. elegans, tyraminergic Rab3-interacting molecules (RIM) neurons co-release tyramine (a small neurotransmitter analog) and FMRFamide-like peptide 18 (FLP-18) (a neuropeptide) in response to mechanical stress. The tyramine immediately suppresses head movement, while the FLP-18 acts on a longer timescale through the natriuretic peptide receptor 5 (NPR-5) to enhance turning and sustain high locomotion speed (Florman and Alkema, 2022). There are several examples to support this model in mammals. They include the dramatic increase in OT release during parturition and lactation as a consequence of hormonal state-dependence, while basal glutamate co-transmission is unaffected, and dendritic peptide release is conditionally enabled by the retraction of glial sheaths (Theodosis et al., 1986a,b); the upregulation of corticotropin-releasing hormone (CRH)/NPY corelease ratio from central amygdala neurons under chronic stress (McGuire et al., 2011); the fasting-dependent selective amplification of NPY release from arcuate neurons without proportional changes in GABA co-transmission that demonstrates an energy-status gating (Tong et al., 2008); and the shift in vagal CCK peptide tone in relation to the gut hormonal state, conditionally enabling or suppressing satiety circuit signaling by ghrelin and leptin (Chung and Heldsinger, 2011).
According to the integrated or synergistic model, peptides and classical transmitters converge on common intracellular pathways, interacting at pre- and postsynaptic levels to produce non-linear amplification or gating of circuit responses. Interaction may occur at the level of second-messenger cascades, receptor heteromerization, or network feedback to produce nascent computational properties that each signal could not generate alone. Because it necessitates the independent regulation of each co-released signal in vivo at physiological concentrations and timescales, interaction is hard to verify scientifically. Many purported synergies could in fact be the result of supraphysiological peptide application-related experimental artifacts. There are several examples of this type of interaction. The co-release of neuropeptides by dopaminergic neurons in the basal ganglia is an example of this integrated type of action, where modulatory interactions alter both motor function and rewards processing (Rice et al., 2011). In the limbic system, the coexistence of glutamate and dynorphin (DYN) is a key functional feature. DYN is often co-released to act as a presynaptic brake, inhibiting further glutamate release and creating a gating mechanism that prevents excitotoxicity and modulates synaptic plasticity processes necessary for learning (Wagner et al., 1993). In the ganglia of the autonomic nervous system (ANS), ACh and luteinizing hormone-releasing hormone (LHRH) provide a classic example of a non-linear temporal response arising from synergistic interactions between the two molecules. Namely, ACh produces a rapid, brief action potential, whereas LHRH generates a slow depolarization that lasts for minutes (Jan and Jan, 1983; Lundberg and Hökfelt, 1983). As a consequence, the neuron shifts from a short-lasting response to sustained excitability. In the cortex and amygdala, GABA is the main inhibitory neurotransmitter, but its effect can be brief. NPY enhances GABAergic signaling at the postsynaptic level and reduces excitatory neurotransmitter release at the presynaptic level (; Molosh et al., 2013). Together, these molecules act as a powerful anti-stress system, “switching off” anxiety-related circuits much more effectively than GABA alone. In mesolimbic rewards areas, NT modulates dopamine signaling by altering the affinity of D2 dopamine receptors. In the presence of the peptide, the dopamine response is amplified, making a stimulus significantly more behaviorally salient (von Euler et al., 1989; Piccart et al., 2015).
According to most available data, these four models represent context-dependent operating modes of the same cotransmission apparatus rather than mutually exclusive alternatives. There are indeed the following unifying variables in support of such an interpretation: the LDCV release probability depends on the firing pattern (burst vs. sparse), vesicle pool composition and postsynaptic receptor sensitivity are determined by the physiological state, signals converge or diverge depending on the target identity, and the same neuron can multiplex over timescales due to the difference between slow peptide volume transmission and quick synaptic transmission. As Nusbaum et al. (2017) clearly discuss and exemplify, cotransmission systems are highly dynamic and best understood when one keeps in mind that the neuron does not use a fixed signaling strategy but instead chooses a combination most appropriate to current computational demand.
3.6 Frequency coding as chemical coding
Without changing anatomical connectivity, peptide recruitment increases computational dimensionality. Neurons, therefore, encode information not only in spike timing but also in the molecular composition of their output messengers (Paul et al., 2017). Such chemical multiplexing may enhance robustness under sustained stimulation, network stability during oscillatory activity, plasticity induction thresholds, and homeostatic compensation (Kundu et al., 2019). However, it also introduces vulnerability: dysregulated peptide release can shift circuit set points, contributing to chronic pain, addiction, epilepsy, or stress-related disorders. In brief, release dynamics convert the dual vesicular architecture into a functional hierarchy of signaling layers. Differences in Ca2+ sensitivity, spatial diffusion, receptor kinetics, and recycling capacity generate stimulus-dependent chemical stratification. Cotransmission thus represents a scalable regulatory system that integrates synaptic precision with network modulation and long-term plasticity. Examining how this layered signaling system evolved and is structured across species is the next obvious step toward better understanding how it operates.
4 Evolutionary origins of cotransmission
Cotransmission is not a late specialization of complex brains, but rather a well-preserved characteristic of neural systems. According to comparative neurobiology, peptide-based signaling predates fast synaptic transmission, and modern dual-transmitter neurons represent evolutionary layering rather than redundancy. The cohabitation of neuropeptides and classical transmitters thus constitutes an accretive design principle driven by rising needs for speed, precision, and computing scalability.
4.1 Peptides: ancestral signaling molecules
Neuropeptides are among the oldest intercellular mediators among metazoans (Jékely, 2021). Peptidergic signaling pathways are present in primitive species such as cnidarians (Grimmelikhuijzen and Westfall, 1995). It is well established that neuropeptides are the main class of transmitters in these animals, but there is evidence that classical low-molecular-weight neurotransmitters are also present in these species. Evidence is moderate-strong for glutamate, moderate for ACh and 5-HT, weak for GABA and catecholamines (Kass-Simon and Scappaticci, 2004; ; Faltine-Gonzalez and Layden, 2019). Based on comparative genomics and neurochemistry, small-molecule neurotransmitters arose after neuropeptide-based signaling, probably coinciding with the emergence of bilaterians about 550–600 million years ago. Glutamatergic and GABAergic systems originated from amino acid metabolism that predates their neurotransmitter roles; their co-option as fast-acting signaling molecules appears to be a bilaterian innovation through convergent evolution (Moroz and Kohn, 2016). Current evidence supports an independent, parallel origin of small-molecular transmitters rather than derivation from neuropeptides, which are considered the more ancestral and indispensable signaling system. In accordance with this line of thought, it is highly unlikely the existence of organisms with only small molecular transmitter systems and no neuropeptides.
Cnidarians have neural networks but lack the complex synaptic mechanisms found in bilaterians. Peptides in these species regulate muscle contractions, feeding, reproduction, and rhythmic behaviors, primarily via diffuse, volume-based communication. Also, the evolutionary age of peptide GPCRs, many of which share similar forms across different animal species, implies that neuromodulatory signaling predated fast ionotropic transmission (Svensson et al., 2019). In early neural systems, peptides most likely functioned as idle integrators of physiological states rather than mediators of rapid responses to internal and/or external changes (Kupfermann and Kandel, 1970; Lloyd et al., 1987; Nassel, 2002; Nässel and Winther, 2010; ; Quiroga et al., 2015; Getz et al., 2020; Kreshchenko et al., 2021). This fundamental modulatory function is still present in contemporary brain circuitry. Even in vertebrates’ highly specialized brains, peptidergic transmission exhibits widespread, state-dependent control, implying that it has evolved rather than been replaced.
4.2 The advent of fast synaptic transmission
The emergence of classical low-molecular-weight neurotransmitters, e.g., glutamate and GABA, which use fast, point-to-point signaling primarily via ligand-gated ion channels, provided a novel means of communication in evolution (Burkhardt and Jékely, 2021). The emergence of specific presynaptic active zones and densely packed postsynaptic densities facilitated millisecond precision and spike-to-spike transmission. Rather than displacing peptidergic systems, rapid synaptic transmission was added to existing modulatory networks (Jékely, 2021). This dual-mode system enabled neural circuits to provide both immediate automatic responses and long-term contextual modification. From an evolutionary perspective, cotransmission may represent the merger of two temporally divergent communication strategies: the ancient, slow, diffuse peptidergic signaling and the more recent, quick, synaptically limited classical transmission. The conservation of both systems in evolution suggests a selective benefit in maintaining chemical variation within individual neurons.
4.3 Cotransmission in invertebrates
Research on invertebrates has helped improve understanding of cotransmission at a fundamental level. Neurons in the mollusk Aplysia californica co-release peptides and classical transmitters that modulate synaptic strength and result in behavioral plasticity (Kupfermann and Kandel, 1970; Lloyd et al., 1987). In this species, peptide cotransmission is crucial for sensitization and habituation of neural networks, revealing the early integration of fast and slow signaling in learning. Similarly, in the arthropod Drosophila melanogaster, multiple neurons express neuropeptides in addition to ACh, glutamate, or GABA. Peptides govern circadian cycles, eating behavior, and stress responses, and they often act across larger cellular domains than classical transmitters (Nassel, 2002; Nässel and Winther, 2010; Venken et al., 2011). Invertebrate data show that cotransmission is not a vertebrate innovation, but rather a general organizational technique. In these simpler creatures, cotransmission typically takes the form of a modulatory intersection: classical transmitters encode individual synaptic events, while peptides regulate circuit gain, excitability thresholds, and behavioral state.
4.4 Vertebrate expansion and functional diversity
With the evolution of vertebrates, the variety of peptides and receptor subtypes increased substantially (Burbach, 2010, 2011). Today, about 70 neuropeptide-encoding genes have been identified. The genes encoding classical neuropeptides are grouped into at least 18 families based on precursor and peptide structure (Burbach, 2011). Gene duplication events expanded the repertoire of neuropeptide precursors and GPCR families, enabling greater modulatory specialization. Cotransmission occurs across almost all major transmitter systems in animals (de Mendoza et al., 2014; Sebé-Pedrós et al., 2018). Glutamatergic neurons may coexpress neuropeptides such as SP or neurotrophins (Merighi et al., 1991; Martin and Finsterwald, 2011); GABAergic interneurons may contain SOM (Watt and Florack, 1993), vasoactive intestinal peptide (VIP) (Brecha et al., 1984), or CCK (Freund and Katona, 2007); monoaminergic neurons can corelease DYNs, NT, or other modulators (Maejima et al., 2013); and autonomic neurons generate a triphasic output comprising ATP, NA, and peptides (Macarthur et al., 2011). Diversification points to evolutionary refinement rather than redundancy. As circuit complexity rose, cotransmission enabled single neurons to encode multidimensional information while preserving anatomical connectedness.
4.5 Evolutionary logic of chemical multiplexing
From an evolutionary standpoint, cotransmission has proven highly advantageous (Vaaga et al., 2014; Svensson et al., 2019; Moroz and Romanova, 2021). Cotransmission enhanced energy efficiency by enabling a single neuron to employ both fast and modulatory signaling pathways, thereby obviating the need for distinct neuronal groups for each function. Furthermore, it conferred context sensitivity; specifically, peptides facilitate state-dependent regulation without necessitating structural alterations. Finally, it facilitated scale plasticity by enabling gene-regulated peptide expression, which enables long-term adaptation to environmental challenges. Finally, dual signaling systems enabled functional diversity while preserving molecular specialization (Toker et al., 2025). The evolutionary trajectory of neural systems appears to reflect an incremental growth in complexity (Jékely, 2021). Peptide-based volume signaling created a modulatory substrate (Zoli et al., 1999; Fuxe and Borroto-Escuela, 2016), whereas fast synaptic transmission provided temporal precision (Krächan et al., 2017). Cotransmission combined the two, enabling layered communication that supports complex behaviors.
As a result, cotransmission should be regarded as an evolutionary stratification of signaling systems, rather than as a violation of a simple neurotransmission principle. Peptidergic communication predated traditional synaptic transmission and serves as a modulatory framework in modern circuits. The development of SCV-based rapid transmission increased speed and spatial precision but did not remove ancestral peptide systems. Rather, chemical multiplexing across both temporal and spatial dimensions was made possible by evolution’s integration of these dimensions into a single neuron. Because coexistence reflects retained biological logic rather than chance chemical overlap, this evolutionary view helps explain its prevalence.
5 Coexistence as a widespread feature of mammalian circuits
The evolutionary and molecular logic of cotransmission becomes fully apparent at the level of systems neuroscience. In mammalian brains, neuropeptide–classical transmitter coexistence is not sporadic but pervasive, embedded within circuits that regulate, among others, cognition, emotion, autonomic balance, sensory processing, and endocrine integration (Figure 4). In this section, some of the best-characterized examples of coexistence and cotransmission will be briefly reviewed.
FIGURE 4
Cortical and hippocampal inhibitory interneurons (Mao and Staiger, 2024) exemplify coexistence within circuit logic. Various GABAergic interneuron subclasses coexpress specific neuropeptides that are associated with their morphology, synaptic targets, and overall network function (Freund and Katona, 2007). For instance, SOM-positive interneurons modulate distal dendritic integration (Takács et al., 2024), whereas CCK- or VIP-containing interneurons affect disinhibitory circuits (Malhotra et al., 2025). Within these cells, GABA mediates rapid inhibitory postsynaptic potentials, while co-released peptides modulate presynaptic transmitter release probability, postsynaptic ionotropic glutamate and GABA receptor phosphorylation, and intrinsic membrane conductance. Consequently, this results in layered inhibition, integrating millisecond-scale synaptic silencing with a more gradual modulation of oscillatory coherence. Furthermore, peptidergic signaling specifically contributes to the tuning of theta and gamma rhythms (Spaak et al., 2012), thereby influencing cognitive functions such as attention and working memory (Hodzic and Riedemann, 2025). Therefore, cotransmission in interneurons extends inhibitory control beyond individual synaptic events, promoting broader network synchronization.
The hippocampus employs distinct signaling mechanisms among neurons to initiate and maintain long-term potentiation (LTP) and long-term depression (LTD) (). Glutamatergic principal neurons may coexpress neuropeptides such as DYN and CCK, whereas hippocampal interneuronal networks contribute peptides including NPY, SOM, VIP, and SP, all of which modulate Ca2+ channel activity, N-methyl-D-aspartate (NMDA) receptor function, and kinase cascades (Katona et al., 2017). In addition, peptide signaling affects the shape of dendritic spines, controls dendritic excitability, alters LTP-induction thresholds, and synchronizes astrocytic responses (Patterson and Yasuda, 2011; Guo et al., 2016; ; Honoré et al., 2021). Peptides link transient activity to continuous signaling, thereby promoting the transition from temporary synaptic changes to more permanent changes in cellular structure. Therefore, cotransmission serves as a biochemical link between electrical activity and gene expression.
The mesolimbic pathways and basal ganglia are prime examples of the synergistic and integrative advantages of cotransmission. Dopaminergic neurons in the midbrain frequently coexpress neuropeptides (gastrin-releasing peptide - GRP, NPY, orexins, cocaine- and amphetamine-regulated transcript - CART, and melanin-concentrating hormone - MCH) that modulate stress responses, rewards prediction, and reinforcement learning (). In the striatum, the simultaneous release of peptides affects the activity of medium spiny neurons, the effects of DA receptor signaling, the intracellular dynamics of cAMP, and synaptic plasticity (Yang et al., 2023). Consequently, this integration affects susceptibility to addiction, motivational disorders, and the development of maladaptive habits. Peptides amplify or gate dopaminergic effects depending on firing pattern and physiological context (Buxton et al., 2017), exemplifying the integrated operational model described earlier.
The hypothalamus provides a striking example of functional asymmetry in cotransmission. Many hypothalamic neurons coexpress classical transmitters (glutamate or GABA) with neuropeptides that act both centrally and peripherally (Ludwig and Leng, 2006). Dendritic peptide release can occur independently of standard axonal transmission, generating spatially dissociated signaling areas in a single neuron (Ludwig and Leng, 2006). Magnocellular neurons, which release OT or AVP, can influence local circuit activity and also activate systemic endocrine pathways. Glutamatergic neurons that respond to stress produce CRH (Tasker et al., 2020). Normally, fast synaptic transmission is the main signaling process; however, during stress, sustained firing triggers peptide release. Peptide signaling intervention changes network excitability and activates the hypothalamic–pituitary–adrenal (HPA) axis. This recruitment, which depends on the state of the organism, shows how cotransmission integrates the neural and endocrine systems, allowing circuit activity to drive changes at the organism level.
Primary sensory pathways provide another clear example of how chemical signals depend on the frequency of neuronal firing. In dorsal root ganglion (DRG) neurons that connect to spinal lamina II, glutamate is released in response to weak stimuli (Uenoyama et al., 2021). However, with ongoing or painful stimulation, SP, CGRP, and BDNF are released together with the transmitter amino acid (Ruscheweyh and Sandkühler, 2002). Electron microscopy showed that nociceptive afferents store peptides and neurotrophic factors in LDCVs (Merighi et al., 1991; ; Salio et al., 2014), which explains how activity alters signal processing. In lamina II, the release of peptides overactivates postsynaptic NMDA receptors, activates microglia and astrocytes, promotes central sensitization, and contributes to chronic pain (Carniglia et al., 2017; Ji et al., 2018). Therefore, cotransmission changes temporary pain signals into lasting hyperexcitability when stimulation continues. In other sensory systems, such as the retina (Brecha et al., 1984; Casini and Brecha, 1991, 1992) and the olfactory bulb (Maher and Westbrook, 2008; Lyons-Warren et al., 2023), peptidergic modulation regulates gain control and temporal filtering, thereby influencing signal-to-noise ratios without altering anatomical connections.
Autonomic neurons are a clear example of hierarchical cotransmission. Sympathetic postganglionic neurons release ATP upon initial activation, NA during moderate activity, and NPY during prolonged, high-frequency stimulation (Cannon et al., 1986; Burnstock et al., 2010). Under various physiological conditions, these three types of messengers regulate, among other things, heart rate and vasoconstriction. Their incremental activation can precisely modulate rapid vasoconstriction, prolonged sympathetic activity, and lasting alterations following stress. In hypertension, e.g., changes in peptide expression can shift the autonomic system toward chronic overactivation (Michel and Rascher, 1995). Similarly, parasympathetic pathways exhibit peptide coexistence, particularly with ACh, involving VIP, PACAP, SP, galanin, and related neuropeptides, which together regulate glandular secretion and smooth muscle function (Michel and Rascher, 1995). Therefore, in both divisions of the ANS, cotransmission allows these circuits to function over different time frames while maintaining a relatively simple structure.
Peptides also affect glial cell function, in addition to their interactions with neurons. Astrocytes and microglia contain neuropeptide receptors, enabling activity-dependent communication between neurons and glia (Carniglia et al., 2017). Peptidergic modulation can control inflammatory responses (Carniglia et al., 2017), synaptic pruning (Nelson et al., 2025), and metabolic support (Nguyen and Dodd, 2024).
6 The changing nature of cotransmitter identity: influences from development, activity, and disease
Cotransmission is not a static characteristic. The concurrent presence of neuropeptides and classical neurotransmitters is dynamically regulated throughout development, in response to physiological changes, and during disease (Hökfelt et al., 2018). Unlike classical transmitters, whose synthetic enzymes are often constitutively expressed, neuropeptide production, as mentioned, is tightly coupled to transcriptional programs. This link renders the peptidergic component of cotransmission particularly sensitive to activity, stress, injury, and environmental signals.
6.1 Peptide expression developmental dynamics
Neuropeptides are often momentarily expressed during embryonic and early postnatal development (Hevesi et al., 2025). These findings support the assessment that cotransmission contributes to the development of neuronal circuits (Vaaga et al., 2014). Many neurons have broader peptidergic profiles than their adult counterparts during crucial developmental periods. These temporarily synthesized peptides may regulate neuronal migration, stimulate synaptogenesis, promote neurite outgrowth, and influence target selection. They are downregulated or restricted to specific neuronal subpopulations as circuits develop (Harkany et al., 2025). This developmental process suggests that peptides first act as guiding signals during network formation, and then assume roles in controlling activity in fully formed circuits. This is clearly exemplified by the role of BDNF (), which is not only a well-recognized neurotrophic factor during development (; ) but also an important modulator of hippocampal LTP (Mizuno et al., 2003; Lu et al., 2014) and nociceptive synapses (Merighi et al., 2004, 2008; ). In line with these observations, peptide synthesis in sensory systems is often higher in early development than in adulthood, with synaptic maturation reflecting the system’s greater adaptability during network formation.
6.2 Activity-dependent transcriptional reprogramming and remodeling caused by disease and injury
The expression of neuropeptides is greatly affected by neuronal activity. Sustained depolarization, synaptic plasticity, stress exposure, or physical injury can all activate transcription factors such as CREB, activator protein-1 (AP-1, composed of c-Fos/c-Jun), and nuclear factor of kappa light-chain enhancer of B cells (NF-κB) (Wang et al., 2018). All of the above conditions can affect the expression of peptide precursor genes, thereby modifying the peptidergic phenotype of a given neuron. Existing peptide genes can be increasingly transcribed, and previously silent peptide genes may be activated. On the contrary, a reduction in baseline peptide expression may occur, along with coordinated changes in receptor expression. For example, stress can reduce glutamatergic transmission and increase CRH expression in the hypothalamus (Tasker et al., 2020). Another example concerns nociceptive pathways, in which central sensitization is facilitated by sustained stimulation, which increases the production of BDNF and SP in primary afferents (Xu et al., 1992; Kerr et al., 1999; Groth and Aanonsen, 2002). These modifications reshape the modulatory overlay rather than necessarily changing the classical transmitter identity. As a result, the neuron modifies its slow signaling output while maintaining its fast synaptic phenotype.
Significant changes in peptidergic expression are frequently due to peripheral nerve damage, neuroinflammation, and neurodegenerative diseases. Axotomy or inflammation can change the number and distribution of LDCVs, promote de novo peptide expression in non-peptidergic neurons, and enhance the production of SP (Weissner et al., 2006), CGRP (Palkovits, 1995), or BDNF (Tonra et al., 1998) in DRG neurons. Normally, primary afferent neurons release glutamate to signal acute harmful stimuli. Persistent or intense stimulation triggers LDCV exocytosis, leading to the co-release of SP, CGRP, and BDNF in the dorsal horn lamina II (Uenoyama et al., 2021, 2024). Synapses formed by primary afferents in the dorsal horn change following injury, as shown by ultrastructural studies, and this remodeling links structural modifications to functional hypersensitivity (Matthews et al., 1992). There are several other examples of remodeling of peptide expression in neurons, e.g., chronic stress modifies peptidergic signaling in limbic networks (Maita et al., 2022), and addiction-related plasticity entails recalibration of dopaminergic tone via peptide-mediated mechanisms (Lüscher and Malenka, 2011). Also, network hyperexcitability in epilepsy may be exacerbated or compensated for by changes in neuropeptide production in inhibitory interneurons (Kovac and Walker, 2013). Therefore, depending on context and time span, cotransmitter plasticity can be either detrimental or adaptive.
6.3 Subcellular compartmentalization and local translation
Some neurons may control peptide availability by translating mRNA locally in dendrites or axons (Jung et al., 2012; Ludwig et al., 2016; Herbison, 2021). Direct demonstrations of neuropeptide local translation are rather uncommon compared with classical somatic synthesis, but several important studies support local dendritic/axonal translation of neuropeptide-related mRNAs. AVP is one of the clearest examples. Its mRNA was shown to localize to the dendrites of hypothalamic magnocellular neurons and undergo local translation (Mohr and Richter, 2004). Related work on OT/AVP magnocellular neurons has demonstrated dendritic trafficking of neuropeptide precursor mRNAs and the local translational machinery associated with secretory activity (). Subcellular regulation of precursor mRNA stability or translation could fine-tune release capacity, even though most neuropeptides are produced in the soma and transported along processes within LDCVs (Sossin and Scheller, 1991). The possible compartment-specific release of different neurotransmitters further complicates cotransmission. Dendritic peptide release occurs in certain neurons independently of classical axonal release (Ludwig and Pittman, 2003). Because dendrites mediate modulatory feedback within local networks, whereas axon terminals are primarily responsible for rapid synaptic output, compartmentalization of release leads to signaling asymmetry (Ludwig et al., 2016). Remarkably, neurons can control incoming and outgoing information streams differently, specifically because of this spatial compartmentalization.
6.4 Homeostatic and metaplastic control
Cotransmission also contributes to homeostatic plasticity (Pozo and Goda, 2010). Peptide expression can modify circuit gain, restoring stability when network activity persists. For instance, sustained downregulation of inhibitory peptides may improve responsiveness, whereas overexpression may promote hyperexcitability (Demarque and Spitzer, 2012). Metaplasticity, the plasticity of synaptic plasticity, augments neural communication, extending its effects beyond simple synaptic scaling (Peineau et al., 2018). This phenomenon can modulate gene expression, thereby impacting synaptic receptor types and excitability thresholds.
Furthermore, alterations in peptide transcription may influence the system’s response to conventional neurotransmitters (Pratelli and Spitzer, 2025). Consequently, cotransmitter plasticity modifies both ongoing signaling and the fundamental principles that dictate future plasticity. Therefore, cotransmitter plasticity demonstrates that neuromessenger coexistence is a dynamic characteristic of gene-regulatory networks. Neurons can alter peptide expression during development, reprogram peptidergic output in response to activity, alter vesicular composition following damage, activate compartment-specific release, and support both maladaptive and homeostatic adaptations. Classical neurotransmitters primarily mediate synaptic functions, whereas neuropeptides exert longer-lasting modulatory influences that shape synaptic plasticity and network adaptation. Thus, cotransmission links short-term activity to long-term phenotypic change by functioning at the nexus of electrophysiology and transcriptional regulation.
7 Pathophysiological consequences of cotransmission
7.1 The detrimental effects of chemical multiplexing
The above-discussed properties that make cotransmission an efficient adaptation process–temporal stratification, gene-regulated plasticity, and network-wide modulation–also leave it susceptible to dysregulation (Figure 4). In various neurological and psychiatric disorders, pathological alterations of peptidergic neurons modify circuit excitability, plasticity thresholds, and homeostatic equilibrium. Cotransmission thus operates at a critical interface between adaptive regulation and disease propagation, as illustrated by the following examples.
Nociceptive pathways provide a clear example of how cotransmission can have negative effects on pain circuitry. The shift from the self-protective short-lasting glutamatergic signaling to sustained peptidergic modulation indicates a transition from defensive nociception to pathological central sensitization (Ji et al., 2018). Several outcomes follow peptide recruitment, including enhanced NMDA receptor function, increased intracellular Ca2+ accumulation, and the activation of microglia and astrocytes (Latremoliere and Woolf, 2009). As a consequence, activation of pro-inflammatory mediators (Mashaghi et al., 2016; Pinho-Ribeiro et al., 2017; Zhu and Bhatia, 2023) and LTP (Willis, 2002; Ruscheweyh et al., 2011) follows at nociceptive synapses. Injury-induced alterations in LCDV density and peptide expression, which reinforce hyperexcitability even after peripheral damage has subsided, further enhance neuronal and circuit function (Walters et al., 2023). Remarkably, a distinct population of DRG neurons that express SOM and GDNF acts antagonistically, thereby reducing nociceptive input to higher centers (Salio et al., 2014; Merighi, 2016, 2017, 2021; Ferrini et al., 2021).
As mentioned previously, dopaminergic neurons within mesolimbic circuits, which are crucial for rewards perception, motivation, and reinforcement learning (), co-express several neuropeptides that regulate synaptic plasticity and DA-modulated behavioral strategies (Dunigan and Roseberry, 2022). Importantly, the glucagon-like peptide-1 receptor 1 (GLP-1R) mediates this modulation, receiving GLP-1 projections from the nucleus of the solitary tract and the intermediate reticular nucleus in the caudal hindbrain (Merkel et al., 2025). Following repeated drug exposure, sustained burst firing enhances peptide release, consequently altering downstream receptor signaling and intracellular cascades. Peptide modulation can increase dopamine receptor sensitivity and alter intracellular signaling pathways, including cAMP-dependent protein kinase (PKA) and extracellular signal-regulated kinase (ERK) cascades, alter synaptic strength in striatal medium spiny neurons, and affect how rewards prediction errors are processed (Iigaya et al., 2019; Shao et al., 2021). These changes then contribute to compulsive drug-seeking behavior and a decrease in behavioral flexibility. As a result, cotransmission is implicated not only in acute reinforcement but also in the long-term reprogramming of motivational circuits. Furthermore, the continued presence of peptidergic signaling could stabilize harmful synaptic states, which would make addiction resistant to extinction.
Peptide cotransmission is a common phenomenon in stress-responsive hypothalamic and limbic circuits. In anxiety and depression, the dysregulation of peptide release disturbs the balance between excitatory and inhibitory neurons (Tao et al., 2024). Such an imbalance results in network hyperresponsiveness or maladaptive stress responses. Several peptides, including CRH, NPY, GRP, and OT, may be dysregulated under different pathophysiological conditions (Rana et al., 2022). Extended stimulation of peptidergic transmission can effectively “lock” neural circuits into a changed equilibrium, thereby diminishing their resilience and adaptive flexibility. Excess CRH over-activates the HPA axis, acting as a powerful modulator that shifts the balance toward fear and anxiety.
Conversely, numerous instances demonstrate that diminished peptidergic signaling can also yield adverse consequences. While neuropeptide NPY is typically viewed as protective, reduced activity or dysfunction during chronic stress can diminish its inhibitory effects, thereby impairing its capacity to mediate stress resilience (Enman et al., 2015). Furthermore, a deficiency in GRP release in the prefrontal cortex (PFC) correlates with elevated anxiety, as this peptide typically regulates fear-related responses (Goto et al., 2022). In addition, decreased OT levels can fail to inhibit CRH neurons, leading to increased anxiety and elevated cortisol secretion under stress (Kuppusamy et al., 2021).
Interneurons in the cortex and hippocampus, which typically express inhibitory peptides and low-molecular-weight neurotransmitters, are crucial for maintaining neural network function (). SOM, e.g., can reduce excitability at both pre- and postsynaptic levels by altering the probability of neurotransmitter release from the presynaptic neuron and the postsynaptic neuron’s response (Katona et al., 2017). Modifications in interneuron peptide expression have been documented, encompassing both compensatory overexpression and pathogenic downregulation, depending on the stage and brain region affected in epilepsy (Marx et al., 2013). Disruption of peptidergic modulation can lower seizure threshold, enhance synchronous firing, and destabilize oscillatory coherence. Because cotransmission affects oscillatory dynamics, its impairment could convert temporary excitatory bursts into continuous epileptiform activity (Drexel and Sperk, 2022).
Chronic stress or hypertension is associated with increased expression and altered release of NPY from sympathetic neurons, which, as mentioned, also contain NA and ATP. Changes in NPY levels lead to prolonged vasoconstriction and sustained sympathetic neuron activation (Robertson et al., 2023). As a result, the ANS shifts from a state of plastic adjustment to a state of constant overactivity. The slow kinetics of peptide signaling may contribute to the chronicity of autonomic dysfunction, making reversal more difficult than modulation of the NA fast transmitter system alone.
Peptidergic signaling also influences neuron–glia interactions. In neurodegenerative diseases, altered peptide release can influence microglial activation, astrocytic metabolic support, synaptic pruning, and the availability of neurotrophic factors (Zhang et al., 2026). A decrease in the support that peptides such as NPY and CRH, acting on synaptic maintenance and astrocyte-dependent pruning, provide could make neurons more vulnerable (Futran-Sheinberg et al., 2025). In contrast, excessive signaling from inflammatory peptides, e.g., SP, might hasten degeneration (Carniglia et al., 2017).
7.2 A brief note on cotransmission as a therapeutic target
The properties of cotransmission discussed in the previous sections offer some therapeutic opportunities (McGonigle, 2012; Todaro et al., 2023). Targeting peptide receptors offers several advantages, including greater specificity due to restricted receptor expression, slower receptor kinetics that may reduce excitotoxic risk, and the possibility to modulate rather than completely suppress fast synaptic transmission (Tang et al., 2026). For these reasons, peptide receptor antagonists or agonists are being evaluated for chronic pain (Rahman et al., 2026), migraine (de Prado and Russo, 2006), stress disorders (Chaki and Kanuma, 2012), and metabolic diseases (). In contrast, the pleiotropic and state-dependent nature of peptidergic signaling requires precise targeting to avoid disrupting adaptive modulation. Future therapies could be envisaged from a better understanding of the operational models of cotransmission–hierarchical, parallel, conditional, or integrated–to design interventions that rebalance rather than silence neural circuits.
In summary, disease states frequently involve a shift in the balance between fast synaptic transmission and slower peptidergic modulation. Because peptide expression is transcriptionally regulated and activity-dependent, maladaptive changes can persist long after the initiating stimulus. Cotransmission thus acts as both amplifier and stabilizer of circuit states. When appropriately regulated, it enhances flexibility and resilience. However, its dysregulation leads to several diseases (Leite et al., 2017). These issues are disturbances of chemical multiplexing rather than mere synaptic irregularities, a clear concept when cotransmission is properly considered a dynamic, stratified signaling system.
8 Methodological advances enabling cotransmission research
The recognition of cotransmission as a fundamental organizational principle of the nervous system was closely associated with methodological and technical advancements. Progress in ultrastructural analysis, molecular profiling, live imaging, and circuit manipulation has deepened our understanding of the complexity of cotransmission. Each technological advance has moved the conceptual framework from mere anatomical features to functional integration and dynamic plasticity.
The initial demonstration of transmitter coexistence and costorage relied on immunohistochemistry and immunoelectron microscopy. Dual and triple immunogold labeling methods enabled visualization of neuropeptides and classical neurotransmitters within the same neuronal profile (Merighi et al., 1988; Merighi and Polak, 1993; Merighi, 2002, 2009). Ultrastructural analyses yielded conclusive evidence of segregation into SCVs and LDCVs within individual boutons. These observations established the morphological foundation for differential release. High-resolution investigations elucidated costorage patterns in primary sensory afferents and other systems, demonstrating, in addition, the concurrent presence of peptides and neurotrophic factors within LDCVs (Salio et al., 2014; Merighi, 2016) and associating vesicular plasticity with pathological conditions. While crucial, ultrastructural immunolabeling is limited by its reliance on images of fixed tissue and by the potential for epitope masking. Nonetheless, it remains crucial for demonstrating vesicular segregation and spatial correlations with nanoscale precision.
Single-cell RNA sequencing (scRNA-seq) has fundamentally changed our understanding of cotransmission. This method allows one to study individual cells within a population, rather than averaging signals across whole groups of neurons, providing unprecedented resolution into cotransmission patterns. Transcriptomic studies have shown that many neurons express genes for both the usual neurotransmitter systems and several neuropeptide precursors (Smith et al., 2019). These transcriptomic datasets also reveal that peptide expression is highly specific to each cell type, that distinct interneuron subclasses are defined by peptide signatures, that injury or stress induces transcriptional reprogramming of peptidergic genes, and that previously unrecognized peptide coexpression patterns exist. Importantly, transcriptomics distinguishes between potential and genuine cotransmission. mRNA presence does not guarantee vesicular packaging or release, but it defines the molecular capacity for coexistence. Combining scRNA-seq with spatial transcriptomics now allows mapping peptide identity and tissue distribution together, bridging molecular profiling with circuit regional anatomy.
Targeted manipulation of genetically defined neuronal populations has enabled the functional examination of cotransmission (Dao et al., 2019). Researchers can isolate the effects of specific cotransmitter combinations by expressing light-sensitive ion channels or engineered receptors within peptide-defined neurons. Furthermore, optogenetic stimulation, when coupled with pharmacological blockade of peptide receptors, permits the experimental dissociation of fast synaptic transmission from slower modulatory influences (Zhang et al., 2019). This approach has clarified certain aspects of frequency-dependent peptide recruitment, some behavioral roles of cotransmission, and circuit-specific modulation. However, short stimulation patterns are frequently used in traditional optogenetic paradigms, which may underestimate peptidergic contributions by failing to trigger LDCV release (). Therefore, it is essential to create stimulation protocols that replicate natural burst firing.
Advancements in genetically encoded fluorescence sensors for neuromodulators and neurotransmitters have created new opportunities for in vivo monitoring of release dynamics (Patriarchi et al., 2020; Ravotto et al., 2020). Peptide detection poses significant technological challenges due to slower kinetics and lower extracellular concentrations, whereas sensors for traditional neurotransmitters such as glutamate and dopamine are well-established. Total internal reflection fluorescence (TIRF) imaging and super-resolution microscopy (Midorikawa, 2018) have enabled visualization of individual vesicular fusion events and differentiation of SCV and LDCV exocytosis based on size and fusion characteristics (Kreutzberger et al., 2019). These methods show distinct release thresholds and kinetics in real time. Very recently, a genetically encoded OT sensor based on G-protein-coupled receptor activation (GRAB), GRABOT1.0, was described. GRABOT1.0 enables imaging of OT release ex vivo and in vivo with suitable sensitivity, specificity, and spatiotemporal resolution (Qian et al., 2023). Two other genetically encoded tools for investigating peptidergic transmission in behaving mice were also developed: a LDCV sensor (CybSEP2) that detects presynaptic neuropeptide release and a silencer (NEPLDCV) that specifically degrades neuropeptides within LDCVs (Kim et al., 2024). The future development and exploitation of peptide-specific optical sensors will be crucial for quantifying the spatial diffusion and temporal persistence of peptidergic signaling in intact circuits.
Mass spectrometry-based proteomics has emerged as a powerful tool for characterizing the molecular makeup of vesicle populations (; Girven et al., 2022). By isolating LDCVs and subsequently performing proteomic analyses, researchers can gain insights into the intricate composition of their contents, including the various auxiliary proteins that play roles in their maturation and transport. Emerging single-vesicle proteomics and nanoscale flow cytometry approaches may determine whether molecularly distinct LDCV subtypes exist within a single neuron. Such a resolution would directly address unresolved questions about the specialization of selective peptide packaging and release (see also Section “9 Unresolved questions and future directions: toward a unified theory of chemical multiplexing”).
Mathematical models integrating Ca2+ dynamics, vesicle pools, receptor kinetics, and diffusion parameters have been used to simulate cotransmission over time (Loewenstein and Sompolinsky, 2003; ; Gandolfi et al., 2021). These models predict the circumstances in which peptides dominate network behavior and show how firing-frequency thresholds translate into non-linear chemical output. Although it remains challenging, incorporating peptidergic modulation into large-scale network simulations is essential for understanding disease states, oscillatory control, and plasticity induction. Tools that can resolve peptide release with the same temporal precision as that currently available for classical transmitters will be necessary for future advancements. These approaches will help clarify whether cotransmission relies on dynamically changing operational modes or rigid hierarchies.
9 Unresolved questions and future directions: toward a unified theory of chemical multiplexing
Cotransmission is still poorly understood at the mechanistic, systems, and computational levels despite decades of research. Although coexistence has been documented and operational models have been identified, basic problems such as vesicle specialization, release selectivity, circuit integration, and therapeutic exploitation remain to be addressed. Addressing these issues will determine whether cotransmission can be fully integrated into mainstream computational and translational neuroscience.
9.1 Are dense-core vesicles functionally heterogeneous?
One of the central unresolved questions concerns the molecular identity of LDCVs within individual neurons. While costorage of multiple peptides within a single vesicle is well documented, it remains unclear whether distinct LDCV subpopulations contain different peptide combinations, or whether vesicle identity encodes functional specialization, or whether release probability varies among vesicle subclasses. In Lymnea stagnalis, cell-type-specific sorting of neuropeptides has been identified as a mechanism to modulate the peptide composition of LDCVs (Klumperman et al., 1996). However, similar observations have been more difficult to replicate in vertebrates. Single-vesicle proteomics and super-resolution imaging may determine whether LDCVs are homogeneous storage units or molecularly stratified compartments. Functional heterogeneity would imply a higher degree of chemical selectivity than currently appreciated.
9.2 Is selective peptide release possible?
Conventional models assume that all peptides within a vesicle are released simultaneously. However, partial fusion (“kiss-and-run”) or regulated pore dilation could, in theory, permit differential discharge of cargo (Rutter and Tsuboi, 2004). It remains to be critically assessed whether specific peptides can be preferentially released under defined Ca2+ conditions, whether vesicle fusion mode influences peptide composition of the extracellular signal, and whether certain peptides are retained within partially fused vesicles. Experimental tools capable of directly visualizing peptide-specific release kinetics are needed to resolve these issues.
9.3 How is cotransmission integrated into neural coding frameworks?
Current models of neural computation emphasize spike timing, firing rate, and synaptic weights. Cotransmission introduces an additional dimension: chemical composition of output. Future theoretical frameworks must incorporate frequency-dependent chemical transitions, spatial diffusion fields, GPCR signaling kinetics, and transcriptional feedback loops. Incorporating these variables into computational models may reveal that cotransmission expands the coding dimensionality beyond classical rate- or temporal-coding schemes (Makadia et al., 2015).
9.4 How does cotransmission interact with glial networks?
Peptide signaling frequently transcends synaptic boundaries, influencing astrocytes and microglia. Nevertheless, the extent to which glial responses reciprocally modulate neuronal cotransmission remains unclear. The potential for glial cells to modulate peptide degradation or diffusion, the impact of glial activation on LDCV release thresholds, and the influence of chronic neuroinflammation on cotransmitter identity remain unresolved (Mazon et al., 2026). Understanding neuron–glial integration will be essential for linking cotransmission to neurodegenerative and inflammatory disorders.
9.5 What determines the operational mode in cotransmission?
As discussed previously, neurons may operate under hierarchical, parallel, conditional, or integrated cotransmission models depending on functional conditions (Svensson et al., 2019). The molecular determinants of these operational states remain unknown. Ca2+ buffering capability, vesicle docking protein composition, receptor density and distribution, transcriptional status, and metabolic environment are examples of potential regulators. Identifying these characteristics would elucidate the mechanisms underlying shifts in circuits between modulatory dominance and rapid, precise signaling.
9.6 Therapeutic targeting: modulation without disruption
Peptide receptors, with their restricted expression and regulatory functions, present appealing therapeutic targets (). However, the pleiotropy and context-dependence inherent in peptidergic signaling present challenges for therapeutic interventions. Future therapeutic approaches should prioritize targeting receptor subtypes within specific circuit nodes, utilizing biased agonism to fine-tune intracellular signaling pathways, and combining molecular targeting with activity-dependent interventions to re-establish balanced cotransmission, rather than simply blocking individual transmitters. Precision neuromodulation may necessitate conceptualizing cotransmission not as additive signaling, but as integrated chemical logic.
9.7 Toward a unified conceptual framework
Cumulative evidence suggests that cotransmission is not an exception to classical neurotransmission but its expansion. A unified framework should consider dual vesicular architecture as a structural substrate, differential Ca2+ sensitivity as an activity integrator, temporal stratification as functional layering, transcriptional plasticity as an adaptive amplifier, and systems integration as a network stabilizer. Such a framework positions cotransmission as a scalable regulatory system capable of converting transient activity into sustained circuit states.
10 Conclusion: cotransmission as a core computational principle of neural systems
The coexistence of neuropeptides and classical neurotransmitters represents far more than a historical correction to an oversimplified interpretation of Dale’s principle. It reflects a deeply conserved organizational strategy that endows neurons with multilayered chemical output. Through dual vesicular architecture, differential Ca2+ sensitivity, spatial divergence of release sites, and transcriptionally regulated plasticity, cotransmission enables temporal and functional stratification of signaling across milliseconds to hours.
From an evolutionary perspective, peptide-based modulation preceded rapid synaptic transmission. Rather than being displaced by the emergence of fast amino acid–mediated signaling, this ancestral modulatory layer was integrated into the same cellular framework. Modern neurons therefore operate as chemical multiplexers, combining precise point-to-point transmission with diffuse, state-dependent modulation. This layered architecture enhances computational dimensionality without increasing anatomical complexity.
Oscillatory coherence, plasticity thresholds, motivational states, endocrine integration, sensory gain control, and autonomic balance are all regulated at the systems level by cotransmission. It links chemical identity to spike frequency, enabling assessment of both signal composition and strength from firing patterns. The transfer of electrical code into molecular diversity increases the coding capacity of neural circuits. Importantly, peptidergic expression plasticity links short-term activity to long-term phenotypic alteration. Cotransmission connects structural remodeling and electrophysiological processes via activating transcriptional pathways. Transcriptional activation is crucial for maintaining balance and adaptability in a healthy state.
In contrast, when peptide signaling goes wrong, it can lead to harmful circuit states in various diseases, resulting in neurodegeneration, chronic pain, addiction, stress disorders, epilepsy, and autonomic dysfunction. Recent technological advances, such as single-cell transcriptomics, circuit manipulation, and ultrastructural studies, have clarified the extent and complexity of cotransmission. However, important questions remain about how best to target therapies, how to incorporate cotransmission into computational models, the differences between vesicles, and the specific mechanisms of neurotransmitter release. Multiscale strategies that connect molecular events to network dynamics and behavior will be necessary to close these gaps.
This review’s main conclusion is that cotransmission should no longer be considered an anomaly or a biological curiosity. It is a basic principle of nervous system computation. Neurons acquire context sensitivity, adaptive resilience, and scalable control by incorporating slow modulatory signaling into fast synaptic architecture. Chemical multiplexing must therefore be included as a fundamental aspect of circuit operation in any future theoretical, experimental, or translational frameworks of nervous function. Determining the stability and fragility of complex nervous systems will require understanding how neurons dynamically balance the levels of classical neurotransmitters and peptides.
Statements
Author contributions
AM: Conceptualization, Data curation, Formal analysis, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. MS: Writing – original draft, Writing – review & editing. LL: Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. The original work described in this paper has been supported by local grants from the University of Turin (all authors) and a grant (Protocollo:2022.AI1358.U1558) from Fondazione CRT (LL).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors AM and LL declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
5-HT, serotonin; ACE, angiotensin-converting enzyme; ACh, acetylcholine; AM, adrenomedullin; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; amy, amygdala; ANP/ANF, atrial natriuretic peptide/factor; ANS, autonomic nervous system; AP, action potential; AP-1, activator protein-1; ATP, adenosine 5′-triphosphate; AVP, vasopressin; BDNF, brain-derived neurotrophic factor; BFCNs, basal forebrain cholinergic neurons; BNP, brain natriuretic peptide; cAMP, cyclic adenosine monophosphate; CART, cocaine- and amphetamine-regulated transcript; CCCP-1, conserved coiled-coil protein 1; CCK, cholecystokinin; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; CNP, C-type natriuretic peptide; CNS, central nervous system; CREB, cyclic AMP response element-binding protein; CRH, corticotropin-releasing hormone; DA, dopamine; DNP, dendroaspis natriuretic peptide; DOR, δ-opioid receptor; DPP4, dipeptidyl peptidase 4; DRG, dorsal root ganglion; DYN, dynorphin; EARP, endosome-associated recycling protein; EIPR-1, EARP-interacting protein 1; EPSC, excitatory postsynaptic current; EPSPs, excitatory post-synaptic potentials; ERK, extracellular signal-regulated kinase; FLP-18, FMRFamide-like peptide 18; GDNF, glial-derived neurotrophic factor; GIP, glucose-dependent insulinotropic polypeptide; GIRK, G protein-coupled inward rectifier K+; GLP, glucagon-like peptide; GLP-1R, glucagon-like peptide-1 receptor 1; GHRH, growth hormone-releasing hormone; GnRH, gonadotropin-releasing hormone; GPCR, G-protein–coupled receptor; GRAB, G-protein-coupled receptor activation; GRKs, G-protein-coupled receptor kinases; GRP, gastrin-releasing peptide; HF, high frequency; HPA, hypothalamic–pituitary–adrenal; IP, inositol phosphate; IP3, inositol triphosphate; KIF1A, kinesin-3; KOR, κ-opioid receptor; LDCV, large dense-core vesicle; LHRH, luteinizing hormone-releasing hormone; LTD, long-term depression; LTP, long-term potentiation; lys, lysosome; MAPK, mitogen-activated protein kinase; MC4R, melanocortin 4 receptor; MCH, melanin-concentrating hormone; MOR, μ-opioid receptor; MSH, melanocyte-stimulating hormone; MSNs, medium spiny neurons; mvb, multivesicular body; NA, noradrenaline; nac, nucleus accumbens; NMDA, N-methyl-D-aspartic acid; NEP, neprilysin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NK1R, neurokinin 1 receptor; NKA, neurokinin A; NKB, neurokinin B; NMDA, N-methyl-D-aspartate; NMJ, neuromuscular junction; NOP, nociceptin/orphanin FQ receptor; NPR-5, natriuretic peptide receptor 5; NPR-B, natriuretic peptide receptor B; NPTX2, neuronal pentraxin 2; NPY, neuropeptide Y; NT, neurotensin; OT, oxytocin; PAC1, pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP, pituitary adenylate cyclase-activating polypeptide; PDYN, prodynorphin; PENK, proenkephalin; PFC, prefrontal cortex; PHI/PHM, peptide histidine isoleucine/methionine; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; PNOC, pronociceptin; PNS, peripheral nervous system; PSNS, parasympathetic nervous system; POMC, pro-opiomelanocortin; PP, pancreatic polypeptide; PVN, paraventricular nucleus; PYY, peptide YY; RAMP1, receptor activity modifying protein 1; RER, rough endoplasmic reticulum; RIM, Rab3-interacting molecules; RTK, receptor tyrosine kinase; SCN, suprachiasmatic nucleus; scRNA-seq, single-cell RNA sequencing; SCV, small clear vesicle; SNAP-25, soluble NSF attachment protein 25; SNARE, SNAP receptor; SNS, sympathetic nervous system; SOM, somatostatin; SON, supraoptic nucleus; SP, substance P; SSV, small synaptic vesicle; TGN, trans-Golgi network; TIRF, total internal reflection fluorescence; TRH, thyrotropin-releasing hormone; VAChT, vesicular acetylcholine transporter; VGAT, vesicular GABA transporter; VGLUT, vesicular glutamate transporter; VIP, vasoactive intestinal peptide; VMAT2, vesicular monoamine transporter 2; VPAC, vasoactive intestinal peptide receptors; VTA/SN, ventral tegmental area/substantia nigra; Y, NPY receptors.
References
1
AbelJ. J. (1899). Ueber den blutdruckerregenden Bestandtheil der Nebenniere, das Epinephrin.Biol. Chem.28318–362. 10.1515/bchm2.1899.28.3-4.318
2
AkilH.WatsonS. J.YoungE.LewisM. E.KhachaturianH.WalkerJ. M. (1984). Endogenous opioids: biology and function.Annu. Rev. Neurosci.7223–255. 10.1146/annurev.ne.07.030184.001255
3
Al-HasaniR.WongJ. M. T.MabroukO. S.McCallJ. G.SchmitzG. P.Porter-StranskyK. A.et al. (2018). In vivo detection of optically-evoked opioid peptide release.eLife7:e36520. 10.7554/eLife.36520
4
AnctilM. (2009). Chemical transmission in the sea anemone Nematostella vectensis: a genomic perspective.Comp. Biochem. Physiol. Part D Genomics Proteomics4268–289. 10.1016/j.cbd.2009.07.001
5
AndermannM. L.LowellB. B. (2017). Toward a wiring diagram understanding of appetite control.Neuron95757–778. 10.1016/j.neuron.2017.06.014
6
AndersonK. D.ReinerA. (1990). Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: an evolutionarily conserved feature of basal ganglia organization.J. Comp. Neurol.295339–369. 10.1002/cne.902950302
7
AokiC.WuK.ElsteA.LenG.LinS.McAuliffeG.et al. (2000). Localization of brain-derived neurotrophic factor and TrkB receptors to postsynaptic densities of adult rat cerebral cortex.J. Neurosci. Res.59454–463. 10.1002/(sici)1097-4547(20000201)59:3<454::aid-jnr21>3.0.co;2-h
8
ApicellaA. J.MarchionniI. (2022). VIP-expressing GABAergic neurons: disinhibitory vs. inhibitory motif and its role in communication across neocortical areas.Front. Cell Neurosci.16:811484. 10.3389/fncel.2022.811484
9
ArrigoniE.SaperC. B. (2014). What optogenetic stimulation is telling us (and failing to tell us) about fast neurotransmitters and neuromodulators in brain circuits for wake-sleep regulation.Curr. Opin. Neurobiol.29165–171. 10.1016/j.conb.2014.07.016
10
ArtalejoC. R.ElhamdaniA.PalfreyH. C. (1998). Secretion: dense-core vesicles can kiss-and-run too.Curr. Biol.8R62–R65. 10.1016/s0960-9822(98)70036-3
11
AsricanB.WootenJ.LiY. D.QuintanillaL.ZhangF.WanderC.et al. (2020). Neuropeptides modulate local astrocytes to regulate adult hippocampal neural stem cells.Neuron108349–366.e6. 10.1016/j.neuron.2020.07.039
12
AteaqueS.MerkourisS.BardeY. A. (2023). Neurotrophin signalling in the human nervous system.Front. Mol. Neurosci.16:1225373. 10.3389/fnmol.2023.1225373
13
BabilonS.MörlK.Beck-SickingerA. G. (2013). Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors.Biol. Chem.394921–936. 10.1515/hsz-2013-0123
14
BacciA.HuguenardJ. R.PrinceD. A. (2002). Differential modulation of synaptic transmission by neuropeptide Y in rat neocortical neurons.Proc. Natl. Acad. Sci.9917125–17130. 10.1073/pnas.012481899
15
BaileyC. J.FlattP. R.ConlonJ. M. (2023). An update on peptide-based therapies for type 2 diabetes and obesity.Peptides161:170939. 10.1016/j.peptides.2023.170939
16
BaliA.SinghN.JaggiA. S. (2014). Neuropeptides as therapeutic targets to combat stress-associated behavioral and neuroendocrinological effects.CNS Neurol Disord. Drug Targets13347–368. 10.2174/1871527313666140314163920
17
BalogG.VoronezhskayaE. E.HiripiL.ElekesK. (2012). Organization of the serotonergic innervation of the feeding (buccal) musculature during the maturation of the pond snail Lymnaea stagnalis: a morphological and biochemical study.J. Comp. Neurol.520315–329. 10.1002/cne.22693
18
BardeY. A. (2025). The physiopathology of brain-derived neurotrophic factor.Physiol. Rev.1052073–2140. 10.1152/physrev.00038.2024
19
BardoniR.GhirriA.SalioC.PrandiniM.MerighiA. (2007). BDNF-mediated modulation of GABA and glycine release in dorsal horn lamina II from postnatal rats.Dev. Neurobiol.67960–975. 10.1002/dneu.20401
20
BardoniR.MerighiA. (2009). “BDNF and trkB mediated mechanisms in the spinal cord,” in Synaptic Plasticity in Pain, ed.MalcangioM. (New York: Springer).
21
BartolomucciA.PossentiR.MahataS. K.Fischer-ColbrieR.LohY. P.SaltonS. R. (2011). The extended granin family: structure, function, and biomedical implications.Endocr. Rev.32755–797. 10.1210/er.2010-0027
22
BaudryM. (2002). “Synapses and synaptic transmission and integration,” in Encyclopedia of the Human Brain (Second Edition), ed.GrafmanJ. H. (Oxford: Elsevier), 545–552.
23
BaylissW. M.StarlingE. H. (1902). The mechanism of pancreatic secretion.J. Physiol.28325–353. 10.1113/jphysiol.1902.sp000920
24
BeaulieuJ. M.GainetdinovR. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors.Pharmacol. Rev.63182–217. 10.1124/pr.110.002642
25
BelloE. P.MateoY.GelmanD. M.NoaínD.ShinJ. H.LowM. J.et al. (2011). Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors.Nat. Neurosci.141033–1038. 10.1038/nn.2862
26
BetkeK. M.WellsC. A.HammH. E. (2012). GPCR mediated regulation of synaptic transmission.Prog. Neurobiol.96304–321. 10.1016/j.pneurobio.2012.01.009
27
BieleckiA.KalitaP.LewandowskiM.SkomorowskiM. (2008). Compartment model of neuropeptide synaptic transport with impulse control.Biol. Cybern.99443–458. 10.1007/s00422-008-0250-0
28
BieverA.Donlin-AspP. G.SchumanE. M. (2019). Local translation in neuronal processes.Curr. Opin. Neurobiol.57141–148. 10.1016/j.conb.2019.02.008
29
Bin IbrahimM. Z.BenoyA.SajikumarS. (2022). Long-term plasticity in the hippocampus: maintaining within and ‘tagging’ between synapses.FEBS J.2892176–2201. 10.1111/febs.16065
30
BinderD. K.ScharfmanH. E. (2004). Brain-derived neurotrophic factor.Growth Fact.22123–131. 10.1080/08977190410001723308
31
BinderE. B.KinkeadB.OwensM. J.NemeroffC. B. (2001). Neurotensin and dopamine interactions.Pharmacol. Rev.53453–486. 10.1016/S0031-6997(24)01509-6
32
BlomqvistA. G.HerzogH. (1997). Y-receptor subtypes–how many more?Trends Neurosci.20294–298. 10.1016/s0166-2236(96)01057-0
33
BockaertJ.ClaeysenS.BécamelC.DumuisA.MarinP. (2006). Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation.Cell Tissue Res.326553–572. 10.1007/s00441-006-0286-1
34
BoweryN. G.BettlerB.FroestlW.GallagherJ. P.MarshallF.RaiteriM.et al. (2002). International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function.Pharmacol. Rev.54247–264. 10.1124/pr.54.2.247
35
BrechaN. C.EldredW.KuljisR. O.KartenH. J. (1984). Chapter 7 Identification and localization of biologically active peptides in the vertebrate retina.Prog. Retinal Res.3185–226. 10.1016/0278-4327(84)90009-9
36
BrodalP. (2016). The Central Nervous System, 5 Edn. New York, NY: Oxford Academic. 10.1093/med/9780190228958.001.0001
37
BrownD. A. (2006). Acetylcholine.Br. J. Pharmacol.147 (Suppl. 1), S120–S126. 10.1038/sj.bjp.0706474
38
BucherD.GoaillardJ. M. (2011). Beyond faithful conduction: short-term dynamics, neuromodulation, and long-term regulation of spike propagation in the axon.Prog. Neurobiol.94307–346. 10.1016/j.pneurobio.2011.06.001
39
BurbachJ. P. (2010). Neuropeptides from concept to online database www.neuropeptides.nl.Eur. J. Pharmacol.62627–48. 10.1016/j.ejphar.2009.10.015
40
BurbachJ. P. (2011). What are neuropeptides?Methods Mol. Biol.7891–36. 10.1007/978-1-61779-310-3_1
41
BurkhardtP.JékelyG. (2021). Evolution of synapses and neurotransmitter systems: the divide-and-conquer model for early neural cell-type evolution.Curr. Opin. Neurobiol.71127–138. 10.1016/j.conb.2021.11.002
42
BurnstockG. (1983). “Recent concepts of chemical communication between excitable cells,” in Dale’s Principle and Communication between Neurones, ed.OsborneN. N. (Oxford, NY: Pergamon Press), 7–35.
43
BurnstockG. (2007). Purine and pyrimidine receptors.Cell Mol. Life Sci.641471–1483. 10.1007/s00018-007-6497-0
44
BurnstockG.FredholmB. B.NorthR. A.VerkhratskyA. (2010). The birth and postnatal development of purinergic signalling.Acta Physiol.19993–147. 10.1111/j.1748-1716.2010.02114.x
45
BuxtonD.BracciE.OvertonP. G.GurneyK. (2017). Striatal neuropeptides enhance selection and rejection of sequential actions.Front. Comput. Neurosci.11:62. 10.3389/fncom.2017.00062
46
CaesteckerS.LescrauwaetE.BoonP.CarretteE.RaedtR.VonckK. (2025). The locus coeruleus—noradrenergic system in the healthy and diseased brain: a narrative review.Eur. J. Neurol.32:e70337. 10.1111/ene.70337
47
CampbellD. J. (2018). Neprilysin inhibitors and bradykinin.Front. Med.5:257. 10.3389/fmed.2018.00257
48
CannevaF.GolubY.DistlerJ.DobnerJ.MeyerS.von HörstenS. (2015). DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY.Psychoneuroendocrinology53195–206. 10.1016/j.psyneuen.2015.01.007
49
CannonB.NedergaardJ.LundbergJ. M.HökfeltT.TereniusL.GoldsteinM. (1986). ’Neuropeptide tyrosine’ (NPY) is co-stored with noradrenaline in vascular but not in parenchymal sympathetic nerves of brown adipose tissue.Exp. Cell Res.164546–550. 10.1016/0014-4827(86)90052-2
50
CárdenasA. M.MarengoF. D. (2016). How the stimulus defines the dynamics of vesicle pool recruitment, fusion mode, and vesicle recycling in neuroendocrine cells.J. Neurochem.137867–879. 10.1111/jnc.13565
51
CarnigliaL.RamírezD.DurandD.SabaJ.TuratiJ.CarusoC.et al. (2017). Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases.Mediat. Inflamm.2017:5048616. 10.1155/2017/5048616
52
CarrawayR.LeemanS. E. (1973). The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami.J. Biol. Chem.2486854–6861.
53
CasiniG.BrechaN. C. (1991). Vasoactive intestinal polypeptide-containing cells in the rabbit retina - Immunohistochemical localization and quantitative analysis.J. Comp. Neurol.305313–327. 10.1002/cne.903050212
54
CasiniG.BrechaN. C. (1992). Colocalization of vasoactive intestinal polypeptide and GABA immunoreactivities in a population of wide-field amacrine cells in the rabbit retina.Vis. Neurosci.8373–378. 10.1017/s0952523800005113
55
ChakiS.KanumaK. (2012). “Neuropeptide receptors: novel therapeutic targets for depression and anxiety disorders,” in Drug Discovery for Psychiatric Disorders, edsRankovicZ.BinghamM.NestlerE. J.HargreavesR. (London: The Royal Society of Chemistry).
56
ChenN.ZhangY.Rivera-RodriguezE. J.YuA. D.HobinM.RosbashM.et al. (2023). Widespread posttranscriptional regulation of cotransmission.Sci. Adv.9:eadg9836. 10.1126/sciadv.adg9836
57
ChowdhuryM. A. R.AnJ.JeongS. (2023). The pleiotropic face of CREB family transcription factors.Mol. Cells46399–413. 10.14348/molcells.2023.2193
58
ChristiansenA. T.SørensenN. B.HaanesK. A.BlixtF. W.la CourM.WarfvingeK.et al. (2018). Neuropeptide Y treatment induces retinal vasoconstriction and causes functional and histological retinal damage in a porcine ischaemia model.Acta Ophthalmol.96812–820. 10.1111/aos.13806
59
ChungO.HeldsingerA. (2011). Vagal control of satiety and hormonal regulation of appetite.J. Neurogastroenterol. Motility17338–348. 10.5056/jnm.2011.17.4.338
60
CifuentesF.MontoyaM.MoralesM. A. (2008). High-frequency stimuli preferentially release large dense-core vesicles located in the proximity of nonspecialized zones of the presynaptic membrane in sympathetic ganglia.Dev. Neurobiol.68446–456. 10.1002/dneu.20604
61
ComerasL. B.HörmerN.Mohan BethurajP.TasanR. O. (2021). NPY released from GABA neurons of the dentate gyrus specially reduces contextual fear without affecting cued or trace fear.Front. Synaptic Neurosci.13:635726. 10.3389/fnsyn.2021.635726
62
CountsS. E.ChenE. Y.CheS.IkonomovicM. D.WuuJ.GinsbergS. D.et al. (2006). Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer’s disease.Dement. Geriatr. Cogn. Disord.21205–214. 10.1159/000090906
63
CowleyM. A.SmartJ. L.RubinsteinM.CerdánM. G.DianoS.HorvathT. L.et al. (2001). Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus.Nature411480–484. 10.1038/35078085
64
CrawleyJ. N.HommerD. W.SkirbollL. R. (1984). Behavioral and neurophysiological evidence for a facilatory interaction between co-existing transmitters: cholecystokinin and dopamine.Neurochem. Int.6755–760. 10.1016/0197-0186(84)90007-x
65
CulhaneK. J.GupteT. M.MadhugiriI.GadgilC. J.SivaramakrishnanS. (2022). Kinetic model of GPCR-G protein interactions reveals allokairic modulation of signaling.Nat. Commun.13:1202. 10.1038/s41467-022-28789-5
66
DahliwalA.GuptaM. (2023). Physiology, Opioid Receptor.Treasure Island, FL: StatPearls Publishing.
67
DahmsP.MentleinR. (1992). Purification of the main somatostatin-degrading proteases from rat and pig brains, their action on other neuropeptides, and their identification as endopeptidases 24.15 and 24.16.Eur. J. Biochem.208145–154. 10.1111/j.1432-1033.1992.tb17168.x
68
DaleH. H. (1935). Pharmacology and nerve-endings. Walter Ernest Dixon memorial lecture for 1934.Proc. R. Soc. Med. Therap. Sect.28319–332.
69
DaoN. C.BrockwayD. F.CrowleyN. A. (2019). In vitro optogenetic characterization of neuropeptide release from prefrontal cortical somatostatin neurons.Neuroscience4191–4. 10.1016/j.neuroscience.2019.08.014
70
De KoninckY.HenryJ. L. (1991). Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation.Proc. Natl. Acad. Sci. U. S. A.8811344–11348. 10.1073/pnas.88.24.11344
71
de LeceaL.KilduffT. S.PeyronC.GaoX.FoyeP. E.DanielsonP. E.et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.Proc. Natl. Acad. Sci. U. S. A.95322–327. 10.1073/pnas.95.1.322
72
de MendozaA.Sebé-PedrósA.Ruiz-TrilloI. (2014). The evolution of the GPCR signaling system in eukaryotes: modularity, conservation, and the transition to metazoan multicellularity.Genome Biol. Evol.6606–619. 10.1093/gbe/evu038
73
De PotterW. P.CoenE. P.De PotterR. W. (1987). Evidence for the coexistence and co-release of [Met]enkephalin and noradrenaline from sympathetic nerves of the bovine vas deferens.Neuroscience20855–866. 10.1016/0306-4522(87)90246-6
74
de PradoB. M.RussoA. F. (2006). CGRP receptor antagonists: a new frontier of anti-migraine medications.Drug Discov. Today Ther. Strateg.3593–597. 10.1016/j.ddstr.2006.11.003
75
De WiedD. (1971). Long term effect of vasopressin on the maintenance of a conditioned avoidance response in rats.Nature23258–60. 10.1038/232058a0
76
De WiedD.VersteegD. H. G. (1979). Neurohypophyseal principles and memory.Federation Proc.382348–2354.
77
De ZoysaA. I.GovinnageJ.GiorlandoF.DoddS.NarayanaswamyJ. C.BerkM. (2026). Emerging neurobiological targets in psychiatric treatment.Eur. Neuropsychopharmacol.105:112767. 10.1016/j.euroneuro.2026.112767
78
DeckerJ. M.WójtowiczA. M.BartschJ. C.LiottaA.BraunewellK. H.HeinemannU.et al. (2010). C-type natriuretic peptide modulates bidirectional plasticity in hippocampal area CA1 in vitro.Neuroscience1698–22. 10.1016/j.neuroscience.2010.04.064
79
DeckerJ. M.WójtowiczA. M.Ul HaqR.BraunewellK. H.HeinemannU.BehrensC. J. (2009). C-type natriuretic peptide decreases hippocampal network oscillations in adult rats in vitro.Neuroscience1641764–1775. 10.1016/j.neuroscience.2009.09.036
80
DefeaK.SchmidlinF.DéryO.GradyE. F.BunnettN. W. (2000). Mechanisms of initiation and termination of signalling by neuropeptide receptors: a comparison with the proteinase-activated receptors.Biochem. Soc. Trans.28419–426.
81
DemarqueM.SpitzerN. C. (2012). Neurotransmitter phenotype plasticity: an unexpected mechanism in the toolbox of network activity homeostasis.Dev. Neurobiol.7222–32. 10.1002/dneu.20909
82
Di AngelantonioS.GiniatullinR.CostaV.SokolovaE.NistriA. (2003). Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells.Br. J. Pharmacol.1391061–1073. 10.1038/sj.bjp.0705337
83
DrexelM.SperkG. (2022). Seizure-induced overexpression of NPY induces epileptic tolerance in a mouse model of spontaneous recurrent seizures.Front. Mol. Neurosci.15:974784. 10.3389/fnmol.2022.974784
84
DugganA. W.FurmidgeL. J. (1994). Probing the brain and spinal cord with neuropeptides in pathways related to pain and other functions.Front. Neuroendocrinol.15:275–300. 10.1006/frne.1994.1011
85
DuniganA. I.RoseberryA. G. (2022). Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards.Addict. Neurosci.2:11. 10.1016/j.addicn.2022.100011
86
EcclesJ. C. (1957). The Physiology of Nerve Cells.London: John Hopkins Press.
87
EcclesJ. C. (1964). The Physiology of Synapses.Berlin: Springer-Verlag.
88
EggermannE.BucurenciuI.GoswamiS. P.JonasP. (2011). Nanodomain coupling between Ca2 + channels and sensors of exocytosis at fast mammalian synapses.Nat. Rev. Neurosci.137–21. 10.1038/nrn3125
89
EidenL. E.HernándezV. S.JiangS. Z.ZhangL. (2022). Neuropeptides and small-molecule amine transmitters: cooperative signaling in the nervous system.Cell Mol. Life Sci.79:492. 10.1007/s00018-022-04451-7
90
EnmanN. M.SabbanE. L.McGonigleP.Van BockstaeleE. J. (2015). Targeting the neuropeptide Y system in stress-related psychiatric disorders.Neurobiol. Stress133–43. 10.1016/j.ynstr.2014.09.007
91
EvaC.MeekJ. L.CostaE. (1985). Vasoactive intestinal peptide which coexists with acetylcholine decreases acetylcholine turnover in mouse salivary glands.J. Pharmacol. Exp. Ther.232670–674.
92
Faltine-GonzalezD. Z.LaydenM. J. (2019). Characterization of nAChRs in Nematostella vectensis supports neuronal and non-neuronal roles in the cnidarian-bilaterian common ancestor.Evodevo10:27. 10.1186/s13227-019-0136-3
93
FariniF. (1913). About diabetes insipidus and hypophysiotherapy.Wien Klin Wochenschr26:1867.
94
FeiH.KrantzD. E. (2009). “Vesicular neurotransmitter transporters,” in Handbook of Neurochemistry and Molecular Neurobiology: Neural Signaling Mechanisms, edsLajthaA.MikoshibaK. (Boston, MA: Springer), 87–137.
95
FerriniF.SalioC.BoggioE. M.MerighiA. (2021). Interplay of BDNF and GDNF in the mature spinal somatosensory system and its potential therapeutic relevance.Curr. Neuropharmacol.191225–1245. 10.2174/1570159x18666201116143422
96
FlormanJ. T.AlkemaM. J. (2022). Co-transmission of neuropeptides and monoamines choreograph the C. elegans escape response.PLoS Genet.18:e1010091. 10.1371/journal.pgen.1010091
97
FrecheD.PannaschU.RouachN.HolcmanD. (2011). Synapse geometry and receptor dynamics modulate synaptic strength.PLoS One6:e25122. 10.1371/journal.pone.0025122
98
FredholmB. B.ChenJ. F.MasinoS. A.VaugeoisJ. M. (2005). Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs.Annu. Rev. Pharmacol. Toxicol.45385–412. 10.1146/annurev.pharmtox.45.120403.095731
99
FreundT. F.KatonaI. (2007). Perisomatic inhibition.Neuron5633–42. 10.1016/j.neuron.2007.09.012
100
FriedG.TereniusL.BrodinE.EfendicS.DockrayG.FahrenkrugJ.et al. (1986). Neuropeptide Y, enkephalin and noradrenaline coexist in sympathetic neurons innervating the bovine spleen. Biochemical and immunohistochemical evidence.Cell Tissue Res.243495–508. 10.1007/bf00218056
101
FröhlichF. (2016). “Chapter 6 - neuronal communication beyond synapses,” in Network Neuroscience, ed.FröhlichF. (San Diego: Academic Press), 73–84.
102
Futran-SheinbergE. J.UrbinaV.NavaS.SanchezD.Guzmán-ValdiviaG.ZetterM. A. (2025). Pro- and anti-inflammatory neuropeptides and glia: the balance between neuroprotection and neuroinflammation.Neuroglia6:35. 10.3390/neuroglia6030035
103
FuxeK.Borroto-EscuelaD. O. (2016). Volume transmission and receptor-receptor interactions in heteroreceptor complexes: understanding the role of new concepts for brain communication.Neural Rege. Res.111220–1223. 10.4103/1673-5374.189168
104
GandolfiD.BoianiG. M.BigianiA.MapelliJ. (2021). Modeling neurotransmission: computational tools to investigate neurological disorders.Int. J. Mol. Sci.22:4565. 10.3390/ijms22094565
105
GetzA. M.JanesT. A.VisserF.ZaidiW.SyedN. I. (2020). Neurotrophic factors and target-specific retrograde signaling interactions define the specificity of classical and neuropeptide cotransmitter release at identified Lymnaea synapses.Sci. Rep.10:13526. 10.1038/s41598-020-70322-5
106
GilsbachR.HeinL. (2008). Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline.Handb. Exp. Pharmacol.184261–288. 10.1007/978-3-540-74805-2_9
107
GingellJ. J.HendrikseE. R.HayD. L. (2019). New insights into the regulation of CGRP-family receptors.Trends Pharmacol. Sci.4071–83. 10.1016/j.tips.2018.11.005
108
GirvenK. S.MangieriL.BruchasM. R. (2022). Emerging approaches for decoding neuropeptide transmission.Trends Neurosci.45899–912. 10.1016/j.tins.2022.09.005
109
GoldsteinM.DeutchA. Y. (1992). Dopaminergic mechanisms in the pathogenesis of schizophrenia.FASEB J.62413–2421. 10.1096/fasebj.6.7.1348713
110
GoodmanR. L.HilemanS. M.NestorC. C.PorterK. L.ConnorsJ. M.HardyS. L.et al. (2013). Kisspeptin, neurokinin B, and dynorphin act in the arcuate nucleus to control activity of the GnRH pulse generator in ewes.Endocrinology1544259–4269. 10.1210/en.2013-1331
111
GotoF.KiyamaY.OgawaI.OkunoH.IchiseT.IchiseH.et al. (2022). Gastrin-releasing peptide regulates fear learning under stressed conditions via activation of the amygdalostriatal transition area.Mol. Psychiatry271694–1703. 10.1038/s41380-021-01408-3
112
GradyE. F.GampP. D.JonesE.BalukP.McDonaldD. M.PayanD. G.et al. (1996). Endocytosis and recycling of neurokinin 1 receptors in enteric neurons.Neuroscience751239–1254. 10.1016/0306-4522(96)00357-0
113
GrimmelikhuijzenC. J.WestfallJ. A. (1995). The nervous systems of cnidarians.Exs727–24. 10.1007/978-3-0348-9219-3_2
114
GrothR.AanonsenL. (2002). Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB, prevent inflammation-induced hyperalgesia.Pain100171–181. 10.1016/s0304-3959(02)00264-6
115
GuoJ.JiY.DingY.JiangW.SunY.LuB.et al. (2016). BDNF pro-peptide regulates dendritic spines via caspase-3.Cell Death Dis.7:e2264. 10.1038/cddis.2016.166
116
HannibalJ.MollerM.OttersenO. P.FahrenkrugJ. (2000). PACAP and glutamate are co-stored in the retinohypothalamic tract.J. Comp. Neurol.418147–155.
117
HarkanyT.HevesiZ.HökfeltT. (2025). Neuropeptide receptors as entry points for developmental vulnerability to drug abuse.Curr. Opin. Neurobiol.95:103125. 10.1016/j.conb.2025.103125
118
HarnoE.Gali RamamoorthyT.CollA. P.WhiteA. (2018). POMC: the physiological power of hormone processing.Physiol. Rev.982381–2430. 10.1152/physrev.00024.2017
119
HayD. L.WalkerC. S. (2017). CGRP and its receptors.Headache57625–636. 10.1111/head.13064
120
HefftS.JonasP. (2005). Asynchronous GABA release generates long-lasting inhibition at a hippocampal interneuron-principal neuron synapse.Nat. Neurosci.81319–1328. 10.1038/nn1542
121
HerbisonA. E. (2021). The dendron and episodic neuropeptide release.J. Neuroendocrinol.33:e13024. 10.1111/jne.13024
122
HermanJ. P.TaskerJ. G. (2016). Paraventricular hypothalamic mechanisms of chronic stress adaptation.Front. Endocrinol.7:137. 10.3389/fendo.2016.00137
123
HevesiZ.HökfeltT.HarkanyT. (2025). Neuropeptides: the evergreen jack-of-all-trades in neuronal circuit development and regulation.Bioessays47:e202400238. 10.1002/bies.202400238
124
HirabayashiT.NakamachiT.ShiodaS. (2018). Discovery of PACAP and its receptors in the brain.J. Headache Pain19:28. 10.1186/s10194-018-0855-1
125
HirasawaM.SchwabY.NatahS.HillardC. J.MackieK.SharkeyK. A.et al. (2004). Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain.J. Physiol.559(Pt 2), 611–624. 10.1113/jphysiol.2004.066159
126
HirokawaN.NiwaS.TanakaY. (2010). Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease.Neuron68610–638. 10.1016/j.neuron.2010.09.039
127
HnaskoT. S.EdwardsR. H. (2012). Neurotransmitter corelease: mechanism and physiological role.Annu. Rev. Physiol.74225–243. 10.1146/annurev-physiol-020911-153315
128
HodzicS.RiedemannT. (2025). Neuropeptidergic systems in psychiatric disorders.Front. Endocrinol.16:1654292. 10.3389/fendo.2025.1654292
129
HökfeltT.BardeS.XuZ.-Q. D.KuteevaE.RüeggJ.Le MaitreE.et al. (2018). Neuropeptide and small transmitter coexistence: fundamental studies and relevance to mental illness.Front. Neural Circ.12:106. 10.3389/fncir.2018.00106
130
HökfeltT.JohanssonO.LjungdahlÅLundbergJ. M.SchultzbergM. (1980a). Peptidergic neurones.Nature284515–521. 10.1038/284515a0
131
HökfeltT.LundbergJ. M.SchultzbergM.JohanssonO.LjungdahlÅRehfeldJ. F. (1980b). “Coexistence of peptides and putative transmitters in neurons,” in Neural Peptides and Neuronal Communication, edsCostaE.TrabucchiM. (New York, NY: Raven Press), 1–23.
132
HonoréE.KhlaifiaA.BossonA.LacailleJ.-C. (2021). Hippocampal somatostatin interneurons, long-term synaptic plasticity and memory.Front. Neural Circ.15:687558. 10.3389/fncir.2021.687558
133
HookV.FunkelsteinL.LuD.BarkS.WegrzynJ.HwangS. R. (2008). Proteases for processing proneuropeptides into peptide neurotransmitters and hormones.Annu. Rev. Pharmacol. Toxicol.48393–423. 10.1146/annurev.pharmtox.48.113006.094812
134
IigayaK.MinouraY.OnimaruH.KotaniS.IzumizakiM. (2019). Effects of feeding-related peptides on neuronal oscillation in the ventromedial hypothalamus.J. Clin. Med.8:292. 10.3390/jcm8030292
135
IllesP.RegenoldJ. T. (1990). Interaction between neuropeptide Y and noradrenaline on central catecholamine neurons.Nature34462–63. 10.1038/344062a0
136
ItoiK.HelmreichD. L.Lopez-FigueroaM. O.WatsonS. J. (1999). Differential regulation of corticotropin-releasing hormone and vasopressin gene transcription in the hypothalamus by norepinephrine.J. Neurosci.195464–5472. 10.1523/jneurosci.19-13-05464.1999
137
JakabR. L.Goldman-RakicP.LeranthC. (1997). Dual role of substance P/GABA axons in cortical neurotransmission: synaptic triads on pyramidal cell spines and basket-like innervation of layer II-III calbindin interneurons in primate prefrontal cortex.Cereb. Cortex7359–373. 10.1093/cercor/7.4.359
138
JanY. N.JanL. Y. (1983). Coexistence and corelease of cholinergic and peptidergic transmitters in frog sympathetic ganglia.Fed. Proc.422929–2933.
139
JärviR.Pelto-HuikkoM.HelenP.HervonenA. (1987). Somatostatin-like immunoreactivity in human sympathetic ganglia.Cell Tissue Res.2491–5. 10.1007/bf00215411
140
JékelyG. (2021). The chemical brain hypothesis for the origin of nervous systems.Philos. Trans. R. Soc. Lond. B. Biol. Sci.376:20190761. 10.1098/rstb.2019.0761
141
JiR. R.NackleyA.HuhY.TerrandoN.MaixnerW. (2018). Neuroinflammation and central sensitization in chronic and widespread pain.Anesthesiology129343–366. 10.1097/aln.0000000000002130
142
JungH.YoonB. C.HoltC. E. (2012). Axonal mRNA localization and local protein synthesis in nervous system assembly, maintenance and repair.Nat. Rev. Neurosci.13308–324. 10.1038/nrn3210
143
Kass-SimonG.ScappaticciA. A. (2004). Glutamatergic and GABAnergic control in the tentacle effector systems of Hydra vulgaris.Hydrobiologia53067–71. 10.1007/s10750-004-2647-7
144
KatonaL.MicklemB.BorhegyiZ.SwiejkowskiD. A.ValentiO.VineyT. J.et al. (2017). Behavior-dependent activity patterns of GABAergic long-range projecting neurons in the rat hippocampus.Hippocampus27359–377. 10.1002/hipo.22696
145
KawaguchiY.KubotaY. (1997). GABAergic cell subtypes and their synaptic connections in rat frontal cortex.Cereb. Cortex7476–486. 10.1093/cercor/7.6.476
146
KecskésM.Henn-MikeN.Agócs-LabodaÁSzõcsS.PetykóZ.VargaC. (2020). Somatostatin expressing GABAergic interneurons in the medial entorhinal cortex preferentially inhibit layer III-V pyramidal cells.Commun. Biol.3:754. 10.1038/s42003-020-01496-x
147
KerrB. J.BradburyE. J.BennettD. L.TrivediP. M.DassanP.FrenchJ.et al. (1999). Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord.J. Neurosci.195138–5148. 10.1523/JNEUROSCI.19-12-05138.1999
148
KiefferB. L.Gavériaux-RuffC. (2002). Exploring the opioid system by gene knockout.Prog. Neurobiol.66285–306. 10.1016/s0301-0082(02)00008-4
149
KimD. I.ParkS.ParkS.YeM.ChenJ. Y.KangS. J.et al. (2024). Presynaptic sensor and silencer of peptidergic transmission reveal neuropeptides as primary transmitters in pontine fear circuit.Cell1875102–5117.e6. 10.1016/j.cell.2024.06.035
150
KimS.WallaceM. L.El-RifaiM.KnudsenA. R.SabatiniB. L. (2022). Co-packaging of opposing neurotransmitters in individual synaptic vesicles in the central nervous system.Neuron1101371–1384.e7. 10.1016/j.neuron.2022.01.007
151
KlumpermanJ.SpijkerS.vanM. J.Sharp-BakerH.SmitA. B.GeraertsW. P. (1996). Cell type-specific sorting of neuropeptides: a mechanism to modulate peptide composition of large dense-core vesicles.J.Neurosci.167930–7940.
152
KovacS.WalkerM. C. (2013). Neuropeptides in epilepsy.Neuropeptides47467–475. 10.1016/j.npep.2013.10.015
153
KrächanE. G.FischerA. U.FrankeJ.FriaufE. (2017). Synaptic reliability and temporal precision are achieved via high quantal content and effective replenishment: auditory brainstem versus hippocampus.J. Physiol.595839–864. 10.1113/jp272799
154
KraenzlinM. E.Ch’ngJ. L.MulderryP. K.GhateiM. A.BloomS. R. (1985). Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones.Regul. Pept.10189–197. 10.1016/0167-0115(85)90013-8
155
KrämerH. H.HeL.LuB.BirkleinF.SommerC. (2009). Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase.Neurobiol. Dis.35177–183. 10.1016/j.nbd.2008.11.002
156
KrauthN. (2025). Tug-of-War: orexin and dynorphin effects on reward processing circuits.J. Neurosci.45:e1979242024. 10.1523/jneurosci.1979-24.2024
157
KreshchenkoN.TereninaN.ErmakovA. (2021). Serotonin signalling in flatworms: an immunocytochemical localisation of 5-HT(7) type of serotonin receptors in Opisthorchis felineus and Hymenolepis diminuta.Biomolecules11:1212. 10.3390/biom11081212
158
KreutzbergerA. J. B.KiesslingV.StroupeC.LiangB.PreobraschenskiJ.GanzellaM.et al. (2019). In vitro fusion of single synaptic and dense core vesicles reproduces key physiological properties.Nat. Commun.10:3904. 10.1038/s41467-019-11873-8
159
KunduS.MajhiS.GhoshD. (2019). Chemical synaptic multiplexing enhances rhythmicity in neuronal networks.Nonlinear Dyn.981659–1668. 10.1007/s11071-019-05277-y
160
KupfermannI.KandelE. R. (1970). Electrophysiological properties and functional interconnections of two symmetrical neurosecretory clusters (bag cells) in abdominal ganglion of Aplysia.J. Neurophysiol.33865–876. 10.1152/jn.1970.33.6.865
161
KuppusamyT.RamaswamyP.PerumalM.SilambananS.Prabu KumarA. (2021). A short note on oxytocin and stress attenuation.Bioinformation17921–923. 10.6026/97320630017921
162
KuriB. A.ChanS. A.SmithC. B. (2009). PACAP regulates immediate catecholamine release from adrenal chromaffin cells in an activity-dependent manner through a protein kinase C-dependent pathway.J. Neurochem.1101214–1225. 10.1111/j.1471-4159.2009.06206.x
163
KwinterD. M.LoK.MafiP.SilvermanM. A. (2009). Dynactin regulates bidirectional transport of dense-core vesicles in the axon and dendrites of cultured hippocampal neurons.Neuroscience1621001–1010. 10.1016/j.neuroscience.2009.05.038
164
LandryM.Vila-PorcileE.HokfeltT.CalasA. (2003). Differential routing of coexisting neuropeptides in vasopressin neurons.Eur. J. Neurosci.17579–589. 10.1046/j.1460-9568.2003.02472.x
165
LangP. A.CromeS. Q.XuH. C.LangK. S.ChapatteL.DeenickE. K.et al. (2020). NK Cells Regulate CD8(+) T cell mediated autoimmunity.Front. Cell Infect. Microbiol.10:36. 10.3389/fcimb.2020.00036
166
LangR.GundlachA. L.HolmesF. E.HobsonS. A.WynickD.HökfeltT.et al. (2015). Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity.Pharmacol. Rev.67118–175. 10.1124/pr.112.006536
167
LatremoliereA.WoolfC. J. (2009). Central sensitization: a generator of pain hypersensitivity by central neural plasticity.J. Pain10895–926. 10.1016/j.jpain.2009.06.012
168
LauJ.FarziA.QiY.HeilbronnR.MietzschM.ShiY.-C.et al. (2018). CART neurons in the arcuate nucleus and lateral hypothalamic area exert differential controls on energy homeostasis.Mol. Metab.7102–118. 10.1016/j.molmet.2017.10.015
169
Le MoineC.BlochB. (1995). D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum.J Comp Neurol355418–426. 10.1002/cne.903550308
170
LeiteJ. A.OrellanaA. M. M.KinoshitaP. F.de MelloN. P.ScavoneC.KawamotoE. M. (2017). “Neuroinflammation and neurotransmission mechanisms involved in neuropsychiatric disorders,” in Mechanisms of Neuroinflammation, ed.Aranda AbreuG. E. (London: IntechOpen).
171
LiuX. G.SandkühlerJ. (1995). The effects of extrasynaptic substance P on nociceptive neurons in laminae I and II in rat lumbar spinal dorsal horn.Neuroscience681207–1218. 10.1016/0306-4522(95)00187-n
172
LloydP. E.KupfermannI.WeissK. R. (1987). Sequence of small cardioactive peptide A: a second member of a class of neuropeptides in Aplysia.Peptides8179–184. 10.1016/0196-9781(87)90184-7
173
LoewensteinY.SompolinskyH. (2003). Temporal integration by calcium dynamics in a model neuron.Nat. Neurosci.6961–967. 10.1038/nn1109
174
LoewiP. (1921). Über humorale übertragbarkeit der herznervenwirkung 1 Mitteilung Pfülgers.Arch.Ges.Physiol.189239–242. 10.1007/BF01722757
175
LohseM. J.MaiellaroI.CalebiroD. (2014). Kinetics and mechanism of G protein-coupled receptor activation.Curr. Opin. Cell Biol.2787–93. 10.1016/j.ceb.2013.11.009
176
LuB.NagappanG.LuY. (2014). “BDNF and synaptic plasticity, cognitive function, and dysfunction,” in Neurotrophic Factors, edsLewinG. R.CarterB. D. (Berlin: Springer), 223–250.
177
LudwigM.AppsD.MenziesJ.PatelJ. C.RiceM. E. (2016). Dendritic release of neurotransmitters.Compr. Physiol.7235–252. 10.1002/cphy.c160007
178
LudwigM.LengG. (2006). Dendritic peptide release and peptide-dependent behaviours.Nat. Rev. Neurosci.7126–136. 10.1038/nrn1845
179
LudwigM.PittmanQ. J. (2003). Talking back: dendritic neurotransmitter release.Trends Neurosci.26255–261. 10.1016/S0166-2236(03)00072-9
180
LudwigM.SternJ. (2015). Multiple signalling modalities mediated by dendritic exocytosis of oxytocin and vasopressin.Philos. Trans. R. Soc. Lond. B Biol. Sci.370:20140182. 10.1098/rstb.2014.0182
181
LundbergJ. M.HökfeltT. (1983). Coexistence of peptides and classical neurotransmitters.Trends Neurosci.6325–333. 10.1016/0166-2236(83)90149-2
182
LundbergJ. M.HökfeltT.AnggärdA.Uvnäs-WallenstenK.BrimijoinS.BrodinE.et al. (1980). “Peripheral peptide neurons: distribution, axonal transport and some aspects of possible function,” in Neural Peptides and Neuronal Communication, edsCostaE.TrabucchiM. (New York: Raven Press), 25–36.
183
LüscherC.MalenkaR. C. (2011). Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling.Neuron69650–663. 10.1016/j.neuron.2011.01.017
184
Lyons-WarrenA. M.TantryE. K.MossE. H.KochukovM. Y.BelfortB. D. W.Ortiz-GuzmanJ.et al. (2023). Co-transmitting interneurons in the mouse olfactory bulb regulate olfactory detection and discrimination.Cell Rep.42:113471. 10.1016/j.celrep.2023.113471
185
MacarthurH.WilkenG. H.WestfallT. C.KoloL. L. (2011). Neuronal and non-neuronal modulation of sympathetic neurovascular transmission.Acta Physiol.20337–45. 10.1111/j.1748-1716.2010.02242.x
186
MaejimaT.MasseckO. A.MarkM. D.HerlitzeS. (2013). Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels.Front. Integr. Neurosci.7:40. 10.3389/fnint.2013.00040
187
MagloireV.MercierM. S.KullmannD. M.PavlovI. (2019). GABAergic interneurons in seizures: investigating causality with optogenetics.Neuroscientist25344–358. 10.1177/1073858418805002
188
MaherB. J.WestbrookG. L. (2008). Co-transmission of dopamine and GABA in periglomerular cells.J. Neurophysiol.991559–1564. 10.1152/jn.00636.2007
189
MaitaI.RoepkeT. A.SamuelsB. A. (2022). Chronic stress-induced synaptic changes to corticotropin-releasing factor-signaling in the bed nucleus of the stria terminalis.Front. Behav. Neurosci.16:903782. 10.3389/fnbeh.2022.903782
190
MakadiaH. K.AndersonW. D.FeyD.SauterT.SchwaberJ. S.VadigepalliR. (2015). Multiscale model of dynamic neuromodulation integrating neuropeptide-induced signaling pathway activity with membrane electrophysiology.Biophys. J.108211–223. 10.1016/j.bpj.2014.11.1851
191
MalhotraS.DonnegerF.FarrellJ. S.DudokB.LosonczyA.SolteszI. (2025). Integrating endocannabinoid signaling, CCK interneurons, and hippocampal circuit dynamics in behaving animals.Neuron1131862–1885. 10.1016/j.neuron.2025.03.016
192
MaoX.StaigerJ. F. (2024). Multimodal cortical neuronal cell type classification.Pflugers Arch.476721–733. 10.1007/s00424-024-02923-2
193
MarcosP.CoveñasR. (2022). Regulation of homeostasis by neuropeptide Y: involvement in food intake.Curr. Med. Chem.294026–4049. 10.2174/0929867328666211213114711
194
MartinJ. L.FinsterwaldC. (2011). Cooperation between BDNF and glutamate in the regulation of synaptic transmission and neuronal development.Commun. Integr. Biol.414–16.
195
MartinezA. N.RameshG.JacobsM. B.PhilippM. T. (2015). Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis.J. Neuroinflamm.12:243. 10.1186/s12974-015-0453-y
196
Martinez DamonteV.PomrenzeM. B.ManningC. E.CasperC.WolfdenA. L.MalenkaR. C.et al. (2023). Somatodendritic release of cholecystokinin potentiates GABAergic synapses onto ventral tegmental area dopamine cells.Biol. Psychiatry93197–208. 10.1016/j.biopsych.2022.06.011
197
MarvizonJ. C.GradyE. F.StefaniE.BunnettN. W.MayerE. A. (1999). Substance P release in the dorsal horn assessed by receptor internalization: NMDA receptors counteract a tonic inhibition by GABA(B) receptors.Eur. J. Neurosci.11417–426. 10.1046/j.1460-9568.1999.00445.x
198
MarxM.HaasC. A.HäusslerU. (2013). Differential vulnerability of interneurons in the epileptic hippocampus.Front. Cell Neurosci.7:167. 10.3389/fncel.2013.00167
199
MashaghiA.MarmalidouA.TehraniM.GraceP. M.PothoulakisC.DanaR. (2016). Neuropeptide substance P and the immune response.Cell Mol. Life Sci.734249–4264. 10.1007/s00018-016-2293-z
200
MatteoliM.HaimannC.Torri-TarelliF.PolakJ. M.CeccarelliB.De CamilliP. (1988). Differential effects of a-latratoxin on exocytosis from small synaptic vesicles and from CGRP-containing large dense core vesicles at the frog neuromuscular junction.Proc. Natl. Acad. Sci. U. S. A.857366–7368. 10.1073/pnas.85.19.7366
201
MatthewsM. A.HoffmannK. D.StoverJ. D. (1992). Ultrastructural characterization of substance-P-immunoreactive synaptic terminals in the cat’s normal and rhizotomized trigeminal subnucleus caudalis.Somatosens. Motor Res.9131–156. 10.3109/08990229209144767
202
MazonC.BettersR.Salmeron-CeballosG.TomaziefskiA.CoffmanC.SimonsonR.et al. (2026). Chronic stress alters neurotransmitter co-expression and disrupts context discrimination in a sex-dependent manner.IBRO Neurosci. Rep.20160–169. 10.1016/j.ibneur.2026.01.003
203
MensW. B.WitterA.van Wimersma GreidanusT. B. (1983). Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): Half-times of disappearance of these neuropeptides from CSF.Brain Res.262143–149. 10.1016/0006-8993(83)90478-x
204
McDonaldM. P.CrawleyJ. N. (1997). Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer’s disease.J. Psychiatry Neurosci.22303–317.
205
McGonigleP. (2012). Peptide therapeutics for CNS indications.Biochem. Pharmacol.83559–566. 10.1016/j.bcp.2011.10.014
206
McGuireJ. L.LarkeL.SalleeF.HermanJ.SahR. (2011). Differential regulation of neuropeptide Y in the amygdala and prefrontal cortex during recovery from chronic variable stress.Front. Behav. Neurosci.5:54. 10.3389/fnbeh.2011.00054
207
MedeirosA. T.GratzS. J.DelgadoA.RittJ. T.Oconnor-GilesK. M. (2024). Ca2+ Channel and Active Zone Protein Abundance Intersects with Input-Specific Synapse Organization to Shape Functional Synaptic Diversity.Cambridge: eLife Sciences Publications, Ltd.
208
MercerA. J.HentgesS. T.MeshulC. K.LowM. J. (2013). Unraveling the central proopiomelanocortin neural circuits.Front. Neurosci.7:19. 10.3389/fnins.2013.00019
209
MerighiA. (2002). Costorage and coexistence of neuropeptides in the mammalian CNS.Progr. Neurobiol.66161–190. 10.1016/s0301-0082(01)00031-4
210
MerighiA. (2009). “Neuropetides and coexistence,” in Encyclopedia of Neuroscience, ed.SquireL. R. (Oxford: Academic Press), 843–849.
211
MerighiA. (2016). Targeting the glial-derived neurotrophic factor and related molecules for controlling normal and pathologic pain.Expert Opin. Therapeut. Targets20193–208. 10.1517/14728222.2016.1085972
212
MerighiA. (2017). “Neuropeptides and coexistence,” in Reference Module in Neuroscience and Biobehavioral Psychology, ed. J. P. Stein (Amsterdam: Elsevier). 10.1016/B978-0-12-809324-5.02310-5
213
MerighiA. (2018). Costorage of high molecular weight neurotransmitters in large dense core vesicles of mammalian neurons.Front. Cell. Neurosci.12:272. 10.3389/fncel.2018.00272
214
MerighiA. (2021). Cross talk of BDNF and GDNF in spinal substantia gelatinosa (Lamina II): focus on circuitry.Adv. Exp. Med. Biol.1331215–229. 10.1007/978-3-030-74046-7_14
215
MerighiA. (2024). Brain-derived neurotrophic factor, nociception, and pain.Biomolecules14:539. 10.3390/biom14050539
216
MerighiA. (2026). “Coexistence of peptides with classical neurotransmitters,” in Oxford Research Encyclopedia of Neuroscience, ed.ShermanM. H. (Oxford: Oxford University Press).
217
MerighiA.CarmignotoG.GobboS.LossiL.SalioC.VergnanoA. M.et al. (2004). Neurotrophins in spinal cord nociceptive pathways.Prog. Brain Res.146291–321. 10.1016/s0079-6123(03)46019-6
218
MerighiA.PolakJ. M. (1993). “Post-embedding immunogold staining,” in Immunohistochemistry II, ed.CuelloA. C. (London: John Wiley & Sons), 229–264.
219
MerighiA.PolakJ. M.FumagalliG.TheodosisD. T. (1989a). Ultrastructural localisation of neuropeptides and GABA in the rat dorsal horn: a comparison of different immunogold labelling techniques.J. Histochem. Cytochem.37529–540. 10.1177/37.4.2564404
220
MerighiA.PolakJ. M.TheodosisD. T. (1989b). Ultrastructural distribution of glutamate in the rat dorsal horn and its colocalisation with some neuropeptides.Eur. J. Neurosci.2:93.
221
MerighiA.PolakJ. M.GibsonS. J.GulbenkianS.ValentinoK. L.PeironeS. M. (1988). Ultrastructural studies on calcitonin gene-related peptide-, tachykinins- and somatostatin-immunoreactive neurones in rat dorsal root ganglia: evidence for the colocalisation of different peptides in single secretory granules.Cell Tiss. Res.254101–109. 10.1007/BF00220022
222
MerighiA.PolakJ. M.TheodosisD. T. (1991). Ultrastructural visualization of glutamate and aspartate immunoreactivities in the rat dorsal horn with special reference to the co-localization of glutamate, substance P and calcitonin gene-related peptide.Neuroscience4067–80. 10.1016/0306-4522(91)90175-n
223
MerighiA.SalioC.GhirriA.LossiL.FerriniF.BetelliC.et al. (2008). BDNF as a pain modulator.Prog. Neurobiol.85297–317. 10.1016/j.pneurobio.2008.04.004
224
MerkelR.HernandezN. S.WeirV.ZhangY.CaffreyA.RichM. T.et al. (2025). An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking.Sci. Adv.11:eadr5051. 10.1126/sciadv.adr5051
225
MichelM. C.RascherW. (1995). Neuropeptide Y: a possible role in hypertension?J. Hypertens.13385–395.
226
MidorikawaM. (2018). Real-time imaging of synaptic vesicle exocytosis by total internal reflection fluorescence (TIRF) microscopy.Neurosci. Res.1361–5. 10.1016/j.neures.2018.01.008
227
MizunoM.YamadaK.HeJ.NakajimaA.NabeshimaT. (2003). Involvement of BDNF receptor TrkB in spatial memory formation.Learn. Mem.10108–115. 10.1101/lm.56003
228
MohrE.RichterD. (2004). Subcellular vasopressin mRNA trafficking and local translation in dendrites.J. Neuroendocrinol.16333–339. 10.1111/j.0953-8194.2004.01176.x
229
MoloshA. I.SajdykT. J.TruittW. A.ZhuW.OxfordG. S.ShekharA. (2013). NPY Y1 receptors differentially modulate GABAA and NMDA receptors via divergent signal-transduction pathways to reduce excitability of amygdala neurons.Neuropsychopharmacology381352–1364. 10.1038/npp.2013.33
230
MondayH. R.YountsT. J.CastilloP. E. (2018). Long-Term plasticity of neurotransmitter release: emerging mechanisms and contributions to brain function and disease.Annu. Rev. Neurosci.41299–322. 10.1146/annurev-neuro-080317-062155
231
MondoloniS.MameliM. (2022). Why stay lonely packaged in a synaptic vesicle when you can be in good company? A GABA-glutamate gathering.Neuron1101280–1283. 10.1016/j.neuron.2022.03.035
232
MontminyM. R.GonzalezG. A.YamamotoK. K. (1990). Regulation of cAMP-inducible genes by CREB.Trends Neurosci.13184–188. 10.1016/0166-2236(90)90045-c
233
MorozL. L.KohnA. B. (2016). Independent origins of neurons and synapses: insights from ctenophores.Philos. Trans. R. Soc. Lond. B Biol. Sci.371:20150041. 10.1098/rstb.2015.0041
234
MorozL. L.RomanovaD. Y. (2021). Selective advantages of synapses in evolution.Front. Cell Dev. Biol.9:726563. 10.3389/fcell.2021.726563
235
MufsonE. J.CountsS. E.PerezS. E.BinderL. (2005). Galanin plasticity in the cholinergic basal forebrain in Alzheimer’s disease and transgenic mice.Neuropeptides39233–237. 10.1016/j.npep.2004.12.005
236
MulvihillK. G. (2019). Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters.Neurochem. Int.12294–105. 10.1016/j.neuint.2018.11.004
237
MuschampJ. W.HollanderJ. A.ThompsonJ. L.VorenG.HassingerL. C.OnvaniS.et al. (2014). Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area.Proc. Natl. Acad. Sci. U. S. A.111E1648–E1655. 10.1073/pnas.1315542111
238
NasselD. R. (2002). Neuropeptides in the nervous system of Drosophila and other insects: multiple roles as neuromodulators and neurohormones.Prog. Neurobiol.681–84. 10.1016/s0301-0082(02)00057-6
239
NässelD. R.WintherÅM. E. (2010). Drosophila neuropeptides in regulation of physiology and behavior.Prog. Neurobiol.9242–104. 10.1016/j.pneurobio.2010.04.010
240
NelsonN.MillerV.BroadieK. (2025). Neuron-to-glia and glia-to-glia signaling directs critical period experience-dependent synapse pruning.Front. Cell Dev. Biol.13:1540052. 10.3389/fcell.2025.1540052
241
NelsonT. S.AllenH. N.KhannaR. (2024). Neuropeptide Y and pain: insights from brain research.ACS Pharmacol. Transl. Sci.73718–3728. 10.1021/acsptsci.4c00333
242
NeuhoferD.KalivasP. (2023). Differential modulation of GABAergic and glutamatergic neurons in the ventral pallidum by GABA and neuropeptides.eneuro10:ENEURO.0404-0422.2023. 10.1523/eneuro.0404-22.2023
243
NguyenL. T.DoddG. T. (2024). Hypothalamic neuronal-glial crosstalk in metabolic disease.Npj Metab. Health Dis.2:27. 10.1038/s44324-024-00026-1
244
NiswenderC. M.ConnP. J. (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease.Annu. Rev. Pharmacol. Toxicol.50295–322. 10.1146/annurev.pharmtox.011008.145533
245
NusbaumM. P.BlitzD. M. (2012). Neuropeptide modulation of microcircuits.Curr. Opin. Neurobiol.22592–601. 10.1016/j.conb.2012.01.003
246
NusbaumM. P.BlitzD. M.MarderE. (2017). Functional consequences of neuropeptide and small-molecule co-transmission.Nat. Rev. Neurosci.18389–403. 10.1038/nrn.2017.56
247
ÖgrenS. O.RazaniH.Elvander-TottieE.KehrJ. (2007). The neuropeptide galanin as an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disorders.Physiol. Behav.92172–179. 10.1016/j.physbeh.2007.05.022
248
OliverG.SchäferE. A. (1895). On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication.J. Physiol.18277–279. 10.1113/jphysiol.1895.sp000565
249
OnoaB.LiH.Gagnon-BartschJ. A.EliasL. A.EdwardsR. H. (2010). Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways.J. Neurosci.307917–7927. 10.1523/jneurosci.5298-09.2010
250
ÖzçeteÖD.BanerjeeA.KaeserP. S. (2024). Mechanisms of neuromodulatory volume transmission.Mol. Psychiatry293680–3693. 10.1038/s41380-024-02608-3
251
PalkovitsM. (1995). Neuropeptide messenger plasticity in CNS neurons following axotomy.Mol. Neurobiol.1091–103. 10.1007/BF02740669
252
ParekhA. B. (2008). Ca2+ microdomains near plasma membrane Ca2+ channels: impact on cell function.J. Physiol.5863043–3054. 10.1113/jphysiol.2008.153460
253
PatelJ. C.SherpaA. D.MelaniR.WitkovskyP.WisemanM. R.O’NeillB.et al. (2024). GABA co-released from striatal dopamine axons dampens phasic dopamine release through autoregulatory GABAA receptors.Cell Rep.43:113834. 10.1016/j.celrep.2024.113834
254
PatelY. C. (1999). Somatostatin and its receptor family.Front. Neuroendocrinol.20:157–198. 10.1006/frne.1999.0183
255
PatriarchiT.MohebiA.SunJ.MarleyA.LiangR.DongC.et al. (2020). An expanded palette of dopamine sensors for multiplex imaging in vivo.Nat. Methods171147–1155. 10.1038/s41592-020-0936-3
256
PattersonM.YasudaR. (2011). Signalling pathways underlying structural plasticity of dendritic spines.Br. J. Pharmacol.1631626–1638. 10.1111/j.1476-5381.2011.01328.x
257
PaulA.CrowM.RaudalesR.HeM.GillisJ.HuangZ. J. (2017). Transcriptional architecture of synaptic communication delineates GABAergic neuron identity.Cell171522–539.e20. 10.1016/j.cell.2017.08.032
258
PeineauS.RabiantK.PierreficheO.PotierB. (2018). Synaptic plasticity modulation by circulating peptides and metaplasticity: involvement in Alzheimer’s disease.Pharmacol. Res.130385–401. 10.1016/j.phrs.2018.01.018
259
PelkeyK. A.ChittajalluR.CraigM. T.TricoireL.WesterJ. C.McBainC. J. (2017). Hippocampal GABAergic inhibitory interneurons.Physiol. Rev.971619–1747. 10.1152/physrev.00007.2017
260
Perez-BonillaP.Santiago-ColonK.LeinningerG. M. (2020). Lateral hypothalamic area neuropeptides modulate ventral tegmental area dopamine neurons and feeding.Physiol. Behav.223:112986. 10.1016/j.physbeh.2020.112986
261
PernowJ. (1988). Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control.Acta Physiol. Scand. Suppl.5681–56.
262
PiH. J.HangyaB.KvitsianiD.SandersJ. I.HuangZ. J.KepecsA. (2013). Cortical interneurons that specialize in disinhibitory control.Nature503521–524. 10.1038/nature12676
263
PiccartE.CourtneyN. A.BranchS. Y.FordC. P.BecksteadM. J. (2015). Neurotensin induces presynaptic depression of D2 dopamine autoreceptor-mediated neurotransmission in midbrain dopaminergic neurons.J. Neurosci.3511144–11152. 10.1523/jneurosci.3816-14.2015
264
Pinho-RibeiroF. A.VerriW. A.Jr.ChiuI. M. (2017). Nociceptor sensory neuron-immune interactions in pain and inflammation.Trends Immunol.385–19. 10.1016/j.it.2016.10.001
265
PotterL. R.YoderA. R.FloraD. R.AntosL. K.DickeyD. M. (2009). Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.Handb. Exp. Pharmacol.191341–366. 10.1007/978-3-540-68964-5_15
266
PozoK.GodaY. (2010). Unraveling mechanisms of homeostatic synaptic plasticity.Neuron66337–351. 10.1016/j.neuron.2010.04.028
267
PratelliM.SpitzerN. C. (2025). Drugs of abuse drive neurotransmitter plasticity that alters behavior: implications for mental health.Front. Behav. Neurosci.19:1551213. 10.3389/fnbeh.2025.1551213
268
QianT.WangH.WangP.GengL.MeiL.OsakadaT.et al. (2023). A genetically encoded sensor measures temporal oxytocin release from different neuronal compartments.Nat. Biotechnol.41944–957. 10.1038/s41587-022-01561-2
269
QuirogaS. Y.Carolina BonillaE.Marcela BolañosD.CarbayoF.LitvaitisM. K.BrownF. D. (2015). Evolution of flatworm central nervous systems: Insights from polyclads.Genet. Mol. Biol.38233–248. 10.1590/s1415-475738320150013
270
RahmanM. M.ShimY. W.KimY. H.ParkC.-K. (2026). Peptides for pain sensation and peptides for pain relief: fighting fire with fire.Biomed. Pharmacother.195:118990. 10.1016/j.biopha.2026.118990
271
RamírezM.PrietoI.BanegasI.SegarraA. B.AlbaF. (2011). Neuropeptidases.Methods Mol. Biol.789287–294. 10.1007/978-1-61779-310-3_18
272
RanaT.BehlT.SehgalA.SinghS.SharmaN.AbdeenA.et al. (2022). Exploring the role of neuropeptides in depression and anxiety.Prog. Neuro-Psychopharmacol. Biol. Psychiatry114:110478. 10.1016/j.pnpbp.2021.110478
273
RavottoL.DuffetL.ZhouX.WeberB.PatriarchiT. (2020). A bright and colorful future for G-protein coupled receptor sensors.Front. Cell. Neurosci.14:67. 10.3389/fncel.2020.00067
274
ReevesK. C.ShahN.MuñozB.AtwoodB. K. (2022). Opioid receptor-mediated regulation of neurotransmission in the brain.Front. Mol. Neurosci.15:919773. 10.3389/fnmol.2022.919773
275
RehfeldJ. F. (2017). Cholecystokinin-from local gut hormone to ubiquitous messenger.Front. Endocrinol.8:47. 10.3389/fendo.2017.00047
276
RetiI. M.ReddyR.WorleyP. F.BarabanJ. M. (2002). Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons.J. Neurochem.821561–1565. 10.1046/j.1471-4159.2002.01141.x
277
RiceM. E.PatelJ. C.CraggS. J. (2011). Dopamine release in the basal ganglia.Neuroscience198112–137. 10.1016/j.neuroscience.2011.08.066
278
RileyS. C.WongE.FindlayJ. K.SalamonsenL. A. (1995). Localization of neutral endopeptidase in the ovine uterus and conceptus during the oestrous cycle and early pregnancy.Reprod. Fertil. Dev.727–33. 10.1071/rd9950027
279
RobertsonC.PatersonD. J.HerringN. (2023). “Chapter 14 - Neuropeptide Y and the autonomic nervous system,” in Primer on the Autonomic Nervous System (Fourth Edition), edsBiaggioniI.BrowningK.FinkG.JordanJ.LowP. A.PatonJ. F. R. (New York, NY: Academic Press), 81–87.
280
RootD. H.ZhangS.BarkerD. J.Miranda-BarrientosJ.LiuB.WangH.-L.et al. (2018). Selective brain distribution and distinctive synaptic architecture of dual glutamatergic-GABAergic neurons.Cell Rep.233465–3479. 10.1016/j.celrep.2018.05.063
281
RoquesB. P.Fournié-ZaluskiM. C.FlorentinD.WaksmanG.SassiA.ChailletP.et al. (1982). New enkephalinase inhibitors as probes to differentiate “enkephalinase” and angiotensin-converting-enzyme active sites.Life Sci.311749–1752. 10.1016/0024-3205(82)90201-6
282
RossiS. G.DickersonI. M.RotundoR. L. (2003). Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression.J. Biol. Chem.27824994–25000. 10.1074/jbc.M211379200
283
RuscheweyhR.SandkühlerJ. (2002). Lamina-specific membrane and discharge properties of rat spinal dorsal horn neurones in vitro.J. Physiol.541(Pt 1), 231–244.
284
RuscheweyhR.Wilder-SmithO.DrdlaR.LiuX. G.SandkühlerJ. (2011). Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy.Mol. Pain7:20. 10.1186/1744-8069-7-20
285
RussellF. A.KingR.SmillieS.-J.KodjiX.BrainS. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology.Physiol. Rev.941099–1142. 10.1152/physrev.00034.2013
286
RussellJ. A. (2018). Fifty years of advances in neuroendocrinology.Brain Neurosci. Adv.2:2398212818812014. 10.1177/2398212818812014
287
RutterG. A.TsuboiT. (2004). Kiss and run exocytosis of dense core secretory vesicles.Neuroreport1579–81. 10.1097/00001756-200401190-00016
288
SakuraiT. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness.Nat. Rev. Neurosci.8171–181. 10.1038/nrn2092
289
SalioC.AverillS.PriestleyJ. V.MerighiA. (2007). Costorage of BDNF and neuropeptides within individual dense-core vesicles in central and peripheral neurons.Dev. Neurobiol.67326–338. 10.1002/dneu.20358
290
SalioC.FerriniF.MuthurajuS.MerighiA. (2014). Presynaptic modulation of spinal nociceptive transmission by glial cell line-derived neurotrophic factor (GDNF).J. Neurosci.3413819–13833. 10.1523/JNEUROSCI.0808-14.2014
291
SalioC.LossiL.FerriniF.MerighiA. (2006). Neuropeptides as synaptic transmitters.Cell Tissue Res.326583–598. 10.1007/s00441-006-0268-3
292
ScharrerE. (1954). Neurosecretion and anterior pituitary in the dog.Experientia10264–266. 10.1007/bf02157400
293
Sebé-PedrósA.ChomskyE.PangK.Lara-AstiasoD.GaitiF.MukamelZ.et al. (2018). Early metazoan cell type diversity and the evolution of multicellular gene regulation.Nat. Ecol. Evol.21176–1188. 10.1038/s41559-018-0575-6
294
SeidahN. G.ChrétienM. (1992). Proprotein and prohormone convertases of the subtilisin family Recent developments and future perspectives.Trends Endocrinol. Metab.3133–140. 10.1016/1043-2760(92)90102-7
295
SergeyevV.HökfeltT.HurdY. (1999). Serotonin and substance P co-exist in dorsal raphe neurons of the human brain.Neuroreport103967–3970. 10.1097/00001756-199912160-00044
296
SeveriniC.ImprotaG.Falconieri-ErspamerG.SalvadoriS.ErspamerV. (2002). The tachykinin peptide family.Pharmacol. Rev.54285–322. 10.1124/pr.54.2.285
297
ShabelS. J.ProulxC. D.PirizJ.MalinowR. (2014). Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment.Science3451494–1498. 10.1126/science.1250469
298
ShaoJ.LiuY.GaoD.TuJ.YangF. (2021). Neural burst firing and its roles in mental and neurological disorders.Front. Cell Neurosci.15:741292. 10.3389/fncel.2021.741292
299
SherwoodN. M.KruecklS. L.McRoryJ. E. (2000). The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily.Endocr. Rev.21619–670. 10.1210/edrv.21.6.0414
300
SinganwadP.TatodeA.QutubM.TaksandeB.UmekarM.TrivediR.et al. (2025). Neuropeptide Y as a multifaceted modulator of neuroplasticity, neuroinflammation, and HPA axis dysregulation: Perceptions into treatment-resistant depression.Neuropeptides112:102538. 10.1016/j.npep.2025.102538
301
SkidgelR. A.EngelbrechtS.JohnsonA. R.ErdösE. G. (1984). Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase.Peptides5769–776. 10.1016/0196-9781(84)90020-2
302
SkidgelR. A.ErdösE. G. (2004). Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies.Peptides25521–525. 10.1016/j.peptides.2003.12.010
303
SmithS. J.SmbülU.GraybuckL. T.CollmanF.SeshamaniS.GalaR.et al. (2019). Single-cell transcriptomic evidence for dense intracortical neuropeptide networks.eLife8. 10.7554/eLife.47889
304
SossinW. S.SchellerR. H. (1991). Biosynthesis and sorting of neuropeptides.Curr. Opin. Neurobiol.179–83. 10.1016/0959-4388(91)90013-w
305
SpaakE.ZeitlerM.GielenS. (2012). Hippocampal theta modulation of neocortical spike times and gamma rhythm: a biophysical model study.PLoS One7:e45688. 10.1371/journal.pone.0045688
306
SüdhofT. C. (2008). “Neurotransmitter release,” in Pharmacology of Neurotransmitter Release, edsSüdhofT. C.StarkeK. (Berlin: Springer Berlin Heidelberg), 1–21.
307
SüdhofT. C. (2012). The presynaptic active zone.Neuron7511–25. 10.1016/j.neuron.2012.06.012
308
SvenssonE.Apergis-SchouteJ.BurnstockG.NusbaumM. P.ParkerD.SchiöthH. B. (2019). General principles of neuronal Co-transmission: insights from multiple model systems.Front. Neural Circ.12:117. 10.3389/fncir.2018.00117
309
TakácsV.BardócziZ.OroszÁMajorA.TarL.BerkiP.et al. (2024). Synaptic and dendritic architecture of different types of hippocampal somatostatin interneurons.PLoS Biol.22:e3002539. 10.1371/journal.pbio.3002539
310
TakamineJ. (1901). Adrenalin the active principle of the suprarenal glands and its mode of preparation.Am. J. Pharm.73, 523–531.
311
TangS.HanE. L.MitchellM. J. (2026). Peptide-functionalized nanoparticles for brain-targeted therapeutics.Drug Deliv. Transl. Res.16741–760. 10.1007/s13346-025-01840-w
312
TaoC.ZhangG.SunW.HuangJ.ZhangL.TaoH. (2024). Excitation-inhibition imbalance in medial preoptic area circuits underlies chronic stress-induced depression-like states.Nat. Commun.15:8575. 10.1038/s41467-024-52727-2
313
TasR. P.ChazeauA.CloinB. M. C.LambersM. L. A.HoogenraadC. C.KapiteinL. C. (2017). Differentiation between oppositely oriented microtubules controls polarized neuronal transport.Neuron961264–1271.e65. 10.1016/j.neuron.2017.11.018
314
TaskerJ. G.Prager-KhoutorskyM.TeruyamaR.LemosJ. R.AmstrongW. E. (2020). Advances in the neurophysiology of magnocellular neuroendocrine cells.J. Neuroendocrinol.32:e12826. 10.1111/jne.12826
315
TasmaZ.HayD. L. (2025). Decoding PACAP signaling: splice variants, pathways and designer drugs.Cephalalgia45:3331024251363560. 10.1177/03331024251363560
316
TatemotoK.MuttV. (1980). Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides.Nature285417–418. 10.1038/285417a0
317
TheodosisD. T.ChapmanD. B.MontagneseC.PoulainD. A.MorrisJ. F. (1986a). Structural plasticity in the hypothalamic supraoptic nucleus at lactation affects oxytocin-, but not vasopressin-secreting neurones.Neuroscience17661–678. 10.1016/0306-4522(86)90038-2
318
TheodosisD. T.MontagneseC.RodriguezF.VincentJ. D.PoulainD. A. (1986b). Oxytocin induces morphological plasticity in the adult hypothalamo-neurohypophysial system.Nature322738–740. 10.1038/322738a0
319
TodaroB.OttalaganaE.LuinS.SantiM. (2023). Targeting peptides: the new generation of targeted drug delivery systems.Pharmaceutics15:1648. 10.3390/pharmaceutics15061648
320
ToddA. J. (2010). Neuronal circuitry for pain processing in the dorsal horn.Nat. Rev. Neurosci.11823–836. 10.1038/nrn2947
321
TokerI. A.Ripoll-SánchezL.GeigerL. T.SussfeldA.SainiK. S.BeetsI.et al. (2025). Divergence in neuronal signaling pathways despite conserved neuronal identity among Caenorhabditis species.Curr. Biol.352927–2945.e7. 10.1016/j.cub.2025.05.036
322
TongQ.YeC. P.JonesJ. E.ElmquistJ. K.LowellB. B. (2008). Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance.Nat. Neurosci.11998–1000. 10.1038/nn.2167
323
TonraJ. R.CurtisR.WongV.ClifferK. D.ParkJ. S.TimmesA.et al. (1998). Axotomy upregulates the anterograde transport and expression of brain-derived neurotrophic factor by sensory neurons.J. Neurosci.184374–4383. 10.1523/jneurosci.18-11-04374.1998
324
TotaB.CerraM. C.GattusoA. (2010). Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a ‘whip-brake’ system of the endocrine heart.J. Exp. Biol.2133081–3103. 10.1242/jeb.027391
325
UenoyamaY.NagaeM.TsuchidaH.InoueN.TsukamuraH. (2021). Role of KNDy neurons expressing kisspeptin, neurokinin B, and dynorphin A as a GnRH pulse generator controlling mammalian reproduction.Front. Endocrinol.12:724632. 10.3389/fendo.2021.724632
326
VaagaC. E.BorisovskaM.WestbrookG. L. (2014). Dual-transmitter neurons: functional implications of co-release and co-transmission.Curr. Opin. Neurobiol.2925–32. 10.1016/j.conb.2014.04.010
327
van den PolA. N. (2012). Neuropeptide transmission in brain circuits.Neuron7698–115. 10.1016/j.neuron.2012.09.014
328
VaudryD.Falluel-MorelA.BourgaultS.BasilleM.BurelD.WurtzO.et al. (2009). Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.Pharmacol. Rev.61283–357. 10.1124/pr.109.001370
329
VaudryH.SeongJ. Y. (2014). Neuropeptide GPCRs in neuroendocrinology.Front. Endocrinol.5:41. 10.3389/fendo.2014.00041
330
VenkenK. J.SimpsonJ. H.BellenH. J. (2011). Genetic manipulation of genes and cells in the nervous system of the fruit fly.Neuron72202–230. 10.1016/j.neuron.2011.09.021
331
VillarM. J.MeisterB.CortesR.ShallingM.MorrisM.HökfeltT. (1990). Neuropeptide gene expression in hypothalamic magnocellular neurons of normal and hypophysectomized rats: a combined immunohistochemical and in situ hybridization study.Neuroscience36181–199. 10.1016/0306-4522(90)90361-7
332
VincentJ. P. (1995). Neurotensin receptors: binding properties, transduction pathways, and structure.Cell Mol. Neurobiol.15501–512. 10.1007/BF02071313
333
ViziE. S.KissJ. P.LendvaiB. (2004). Nonsynaptic communication in the central nervous system.Neurochem. Int.45443–451. 10.1016/j.neuint.2003.11.016
334
VoetsT.MoserT.LundP. E.ChowR. H.GeppertM.SüdhofT. C.et al. (2001). Intracellular calcium dependence of large dense-core vesicle exocytosis in the absence of synaptotagmin I.Proc. Natl. Acad. Sci. U. S. A.9811680–11685. 10.1073/pnas.201398798
335
von den VeldenR. (1913). The kidney effects of hypophysis extracts in humans.Berl Klin Wochenschr50.
336
von EulerG.FuxeK.BenfenatiF.HanssonT.AgnatiL. F.GustafssonJ. A. (1989). Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene.Acta Physiol. Scand.135443–448. 10.1111/j.1748-1716.1989.tb08602.x
337
von EulerU. S. (1946). A specific sympathomimetric ergone in adrenergic nerve fibres (Sympathin) and its relations to adrenaline and nor-adrenaline.Acta Physiol. Scand.1273–97. 10.1111/j.1748-1716.1946.tb00368.x
338
WagnerJ. J.TermanG. W.ChavkinC. (1993). Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus.Nature363451–454. 10.1038/363451a0
339
WagnerL.WolfR.ZeitschelU.RossnerS.PetersénÅLeavittB. R.et al. (2015). Proteolytic degradation of neuropeptide Y (NPY) from head to toe: identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery.J. Neurochem.1351019–1037. 10.1111/jnc.13378
340
WaltersE. T.CrookR. J.NeelyG. G.PriceT. J.SmithE. S. J. (2023). Persistent nociceptor hyperactivity as a painful evolutionary adaptation.Trends Neurosci.46211–227. 10.1016/j.tins.2022.12.007
341
WangH.XuJ.LazaroviciP.QuirionR.ZhengW. (2018). cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia.Front. Mol. Neurosci.11:255. 10.3389/fnmol.2018.00255
342
WangM.WangL.XuW.ChuZ.WangH.LuJ.et al. (2024). NeuroPep 2.0: an updated database dedicated to neuropeptide and its receptor annotations.J. Mol. Biol.436:168416. 10.1016/j.jmb.2023.168416
343
WangY.Toledo-RodriguezM.GuptaA.WuC.SilberbergG.LuoJ.et al. (2004). Anatomical, physiological and molecular properties of Martinotti cells in the somatosensory cortex of the juvenile rat.J. Physiol.561(Pt 1), 65–90. 10.1113/jphysiol.2004.073353
344
WatanabeS.TrimbuchT.Camacho-PérezM.RostB. R.BrokowskiB.Söhl-KielczynskiB.et al. (2014). Clathrin regenerates synaptic vesicles from endosomes.Nature515228–233. 10.1038/nature13846
345
Waterman-StorerC. M.KarkiS. B.KuznetsovS. A.TabbJ. S.WeissD. G.LangfordG. M.et al. (1997). The interaction between cytoplasmic dynein and dynactin is required for fast axonal transport.Proc. Natl. Acad. Sci.9412180–12185. 10.1073/pnas.94.22.12180
346
WattC. B.FlorackV. J. (1993). Double-label analyses of the coexistence of somatostatin with GABA and glycine in amacrine cells of the larval tiger salamander retina.Brain Res.617131–137. 10.1016/0006-8993(90)90879-g
347
WeissnerW.WintersonB. J.Stuart-TilleyA.DevorM.BoveG. M. (2006). Time course of substance P expression in dorsal root ganglia following complete spinal nerve transection.J. Comp. Neurol.49778–87. 10.1002/cne.20981
348
WillisW. D. (2002). Long-term potentiation in spinothalamic neurons.Brain Res. Rev.40202–214.
349
WinklerH.Fischer-ColbrieR. (1998). Regulation of the biosynthesis of large dense-core vesicles in chromaffin cells and neurons.Cell Mol. Neurobiol.18193–209. 10.1023/a:1022516919932
350
WinklerH.SchmidleT.FischercolbrieR.KapelariS. (1991). Membrane antigens of endocrine, large dense-core and small synaptic vesicles.Biochem. Soc. Trans.1979–79. 10.1042/bst0190079
351
WongM. -ÁZhouC.ShakiryanovaD.LloydT. -ÁDeitcherD. -ÁLevitanE. -Á (2012). Neuropeptide delivery to synapses by long-range vesicle circulation and sporadic capture.Cell1481029–1038. 10.1016/j.cell.2011.12.036
352
WoolfC. J.SalterM. W. (2000). Neuronal plasticity: increasing the gain in pain.Science2881765–1769.
353
Wrobel GoldbergS.SilbersteinS. D. (2015). Targeting CGRP: a new era for migraine treatment.CNS Drugs29443–452. 10.1007/s40263-015-0253-z
354
XuX. J.DalsgaardC. J.Wiesenfeld-HallinZ. (1992). Spinal substance P and N-methyl-D-aspartate receptors are coactivated in the induction of central sensitization of the nociceptive flexor reflex.Neuroscience51641–648. 10.1016/0306-4522(92)90303-J
355
YangR.TuanR. R. L.HwangF. J.BloodgoodD. W.KongD.DingJ. B. (2023). Dichotomous regulation of striatal plasticity by dynorphin.Mol. Psychiatry28434–447. 10.1038/s41380-022-01885-0
356
ZaidiM.BreimerL. H.MacIntyreI. (1987). Biology of peptides from the calcitonin genes.Q. J. Exp. Physiol.72371–408. 10.1113/expphysiol.1987.sp003084
357
ZhangX.BaoH.HuJ.RenW.HeZ.Yu-TaegerL.et al. (2026). Neuropeptide–GPCR regulation of the neuroimmune axis in neurodegeneration: mechanisms and translation.Bioconjugate Chem.37479–493. 10.1021/acs.bioconjchem.5c00637
358
ZhangY.CastroD. C.HanY.WuY.GuoH.WengZ.et al. (2019). Battery-free, lightweight, injectable microsystem for in vivo wireless pharmacology and optogenetics.Proc. Natl. Acad. Sci.11621427–21437. 10.1073/pnas.1909850116
359
ZhangZ.WuY.WangZ.DunningF. M.RehfussJ.RamananD.et al. (2011). Release mode of large and small dense-core vesicles specified by different synaptotagmin isoforms in PC12 cells.Mol. Biol. Cell222324–2336. 10.1091/mbc.E11-02-0159
360
ZhuZ.BhatiaM. (2023). Inflammation and organ injury the role of substance P and its receptors.Int. J. Mol. Sci.24. 10.3390/ijms24076140
361
ZoliM.AgnatiL. F.JanssonA.FuxeK.SykováE. (1999). Volume transmission in the CNS and its relevance for neurophyschopharmacology.Trends Physiol. Sci.20142–150. 10.1016/s0165-6147(99)01343-7
Summary
Keywords
circuit dynamics, cotransmission, dense-core vesicles, neural coding, neuromodulation, neuropeptides, synaptic plasticity, volume transmission
Citation
Merighi A, Sbriz M and Lossi L (2026) Chemical multiplexing in the nervous system: molecular architecture, functional stratification, and pathophysiological plasticity of neuropeptide-classical neurotransmitter cotransmission. Front. Mol. Neurosci. 19:1839947. doi: 10.3389/fnmol.2026.1839947
Received
26 March 2026
Revised
27 May 2026
Accepted
28 May 2026
Published
22 June 2026
Volume
19 - 2026
Edited by
Cesar Ceballos, Florida Atlantic University, United States
Reviewed by
Carlos A. Matos, University of Algarve, Portugal
Le Wang, University of California, San Diego, United States
Updates
Copyright
© 2026 Merighi, Sbriz and Lossi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adalberto Merighi, adalberto.merighi@unito.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.